#cancersm Transcript
Healthcare social media transcript of the #cancersm hashtag.
– ().
See #cancersm Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | Christina Lizaso @btrfly12 RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | #LCSM Chat @lcsmchat RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | Faces of Lung Cancer @LungCancerFaces RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | Jamie Holloway, PhD @jamienholloway Ready for tonight's chat: Basics of Biomarker Testing! #cancersm |
 | Liz Salmi @TheLizArmy RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I’m your moderator, Tim Allen (@timallenmdjd) Pulmonary pathologist. Professor and Chair of the Department of Pathology at the University of Mississippi Medical Center @UMMCnews @UMMC_Pathology in Jackson, Mississippi #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher #Myeloma peeps join in tonight's #cancersm chat #MMSM |
 | Bob Steele @steele_bob Good evening folks. Bob here from Greensboro, NC. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: I’m your moderator, Tim Allen (@timallenmdjd) Pulmonary pathologist. Professor and Chair of the Department of Pathology at the University of Mississippi Medical Center @UMMCnews @UMMC_Pathology in Jackson, Mississippi #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @jamienholloway: Ready for tonight's chat: Ready for tonight's chat: Basics of Biomarker Testing! #cancersm |
 | Shiela Appavoo MD @ShielaAppavoo RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
| Bob Steele @steele_bob RT @LungCancerFaces: Remember #LCSM friends, for tonight’s chat we will use the #CANCERSM hashtag! https://t.co/pesMIAior5 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: I’m your moderator, Tim Allen (@timallenmdjd) Pulmonary pathologist. Professor and Chair of the Department of Pathology at the University of Mississippi Medical Center @UMMCnews @UMMC_Pathology in Jackson, Mississippi #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD We'll get started in a few minutes -- please take a moment to introduce yourselves. #cancersm |
 | Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
 | Janet Freeman-Daily @JFreemanDaily Hi everyone! Welcome to the pancancer #CANCERSM chat on "Basics of Biomarkers Testing"! Remember to us #cancersm instead of other cancer hashtags (like #LCSM #BCSM #BTSM @GYCSM etc.) |
| #LCSM Chat @lcsmchat Deana Hendrickson @LungCancerFaces in Los Angeles here. Calling all #lcsm lung cancer people to tonight’s #CANCERSM Chat on biomarkers. |
 | Israh Akhtar Khan @israhkhan RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
 | Loves Mashed Potatoes @glostaMAssachu Hello all! Betsy from Gloucester, MA here #cancersm |
| Bob Steele @steele_bob RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LungCancerFaces: Remember #LCSM friends, for tonight’s chat we will use the #CANCERSM hashtag! https://t.co/pesMIAior5 |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Matthew Katz, MD 🟦 @subatomicdoc Good evening, Matt Katz, radiation oncologist joining from Massachusetts. I hope everyone is well, looking forward to #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
| Janet Freeman-Daily @JFreemanDaily RT @jamienholloway: Ready for tonight's chat: Ready for tonight's chat: Basics of Biomarker Testing! #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: I’m your moderator, Tim Allen (@timallenmdjd) Pulmonary pathologist. Professor and Chair of the Department of Pathology at the University of Mississippi Medical Center @UMMCnews @UMMC_Pathology in Jackson, Mississippi #cancersm |
| Jamie Holloway, PhD @jamienholloway I'm Jamie-- cancer scientist and advocate in the DC area. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: We'll get started in a few minutes -- please take a moment to introduce yourselves. #cancersm |
| Janet Freeman-Daily @JFreemanDaily RT @MyelomaTeacher: #Myeloma peeps join in tonight's #cancersm chat #MMSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Hi everyone! Welcome to the pancancer #CANCERSM chat on "Basics of Biomarkers Testing"! Remember to us #cancersm instead of other cancer hashtags (like #LCSM #BCSM #BTSM @GYCSM etc.) |
 | National Cancer Institute @theNCI The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
 | Pub Health Monitor @monitor_PH RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher Cindy - from NJ living with multiple myeloma #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD If you prefer just to listen, please tweet "#cancersm” so we know you’re in the audience (but I urge you ahead and join in! |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/qcE5TUfeLp |
 | Alicia C. Staley @stales RT @TimAllenMDJD: More info about #cancersm and our topic “Basics of Biomarker Testing” can be found at https://t.co/FaMTn7FjgF |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Please do not promote products or services on the #cancersm feed or during the chat. Feel free to share vetted online resources. |
| #LCSM Chat @lcsmchat RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| Alicia C. Staley @stales RT @TimAllenMDJD: If you prefer just to listen, please tweet "#cancersm” so we know you’re in the audience #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD If you change someone’s words when you retweet, please label it MT (modified tweet). #cancersm |
 | PF Anderson @pfanderson@disabled.social @pfanderson RT @jamienholloway: Ready for tonight's chat: Ready for tonight's chat: Basics of Biomarker Testing! #cancersm |
| Christina Lizaso @btrfly12 Hi All - I'm passionate about community engagement and cancer. Co-founder w/ @womenofteal of #gyncsm for gynecologic cancers. Love it when the cancer communities collaborate. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: I’m your moderator, Tim Allen (@timallenmdjd) Pulmonary pathologist. Professor and Chair of the Department of Pathology at the University of Mississippi Medical Center @UMMCnews @UMMC_Pathology in Jackson, Mississippi #cancersm |
| Janet Freeman-Daily @JFreemanDaily RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| Alicia C. Staley @stales RT @TimAllenMDJD: Please do not promote products or services on the #cancersm feed or during the chat |
| Israh Akhtar Khan @israhkhan Learn more about cancer, @ #CANCERSM |
| Alicia C. Staley @stales @theNCI Hi there! #cancersm |
 | Matthew Steliga MD FACS @SteligaMD Hello, #cancersm- following along from Little Rock. |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Please do not promote products or services on the #cancersm feed or during the chat. Feel free to share vetted online resources. |
 | #BTSM chat @BTSMchat Hello #BTSM community: The #cancersm chat is happening RIGHT NOW. Use #cancersm in all of your tweets to join the discussion about the basics of biomarker testing! Do you know YOUR biomarkers?! |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: If you change someone’s words when you retweet, please label it MT (modified tweet). #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/9aLQySh2dV) will not display tweets longer than 140. #cancersm |
| Jamie Holloway, PhD @jamienholloway @lcsmchat Thx! Glad to join this pancancer chat! Thx for hosting! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson Grateful for the invite to #CANCERSM (and that I finally got it on my calendar in the right place!) Excited to learn and share about biomarkers. |
| Liz Salmi @TheLizArmy RT @BTSMchat: Hello #BTSM community: Hello #BTSM community: The #cancersm chat is happening RIGHT NOW. Use #cancersm in all of your tweets to join the discussion about the basics of biomarker testing! Do you know YOUR biomarkers?! |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: Please do not promote products or services on the #cancersm feed or during the chat. Feel free to share vetted online resources. |
| Matthew Katz, MD 🟦 @subatomicdoc RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
 | Peggy Dennis @peggyddennis Hello! Following from Denver #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Glad to see #cancersm Twitter handles participating tonight! #GoTeam |
| Alicia C. Staley @stales Hey #BCSM crew: The #cancersm chat is happening now! |
| Janet Freeman-Daily @JFreemanDaily Janet Freeman-Daily in Seattle here--writer, science geek, lung cancer patient research advocate (https://t.co/OBCc87ZwkG) #CANCERSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @btrfly12: Hi All - I'm passionate about community engagement and cancer. Co-founder w/ @womenofteal of #gyncsm for gynecologic cancers. Love it when the cancer communities collaborate. #cancersm |
 | LungCancer.net @LungCancer_HU Margot here! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: Please do not promote products or services on the #cancersm feed or during the chat. Feel free to share vetted online resources. |
| Matthew Steliga MD FACS @SteligaMD RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I will announce FIVE topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #cancersm |
| Alicia C. Staley @stales I'm Alicia - Co-founder of #BCSM. 3x cancer survivor - Thanks for hosting tonight's chat! #cancersm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Please do not promote products or services on the #cancersm feed or during the chat. Feel free to share vetted online resources. |
| Bob Steele @steele_bob Wife & I are both cancer survivors (breast, melanoma) but lung cancer advocates in honor of my dad who passed at young age of 58. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Note: Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/9aLQySh2dV) will not display tweets longer than 140. #cancersm |
| Alicia C. Staley @stales @lcsmchat @theNCI Hello, hello! #CancerSM |
| LungCancer.net @LungCancer_HU RT @LungCancerFaces: Remember #LCSM friends, for tonight’s chat we will use the #CANCERSM hashtag! https://t.co/pesMIAior5 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @steele_bob: Wife & I are both cancer survivors (breast, melanoma) but lung cancer advocates in honor of my dad who passed at young age of 58. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Glad to see #cancersm Twitter handles participating tonight! #GoTeam |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: I will announce FIVE topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD We’ll start with Topic T1 in a minute … #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage Hi everyone! I’m Darcy oncology nurse from Delaware looking forward to tonight’s chat! #CANCERSM |
 | Amanda Narod @AmandaBinDC @JFreemanDaily @gycsm Awesome! Amanda in DC. Previvor brca2+ patient advocate & cancer communications professional. Lurking and following along. #cancersm. |
| Liz Salmi @TheLizArmy @TimAllenMDJD Liz here from the #BTSM/brain tumor social media community! I'm living with grade II astrocytoma and I have biomarkers! I am IDH-1 positive, ATRX negative. BOOM! Overshare. #cancersm https://t.co/aTlYGCLgKt |
| Israh Akhtar Khan @israhkhan Good evening everyone, I am a Pathologist with expertise in cytopathology, breast,& pulmonary pathology #CANCERSM |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @theNCI Glad to see you here! #MMSM #cancersm |
 | Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD Neuro-onc checking in for #btsm representation for #cancersm #biomarkers 🙌🏻 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T1: What is a biomarker and how is it identified? #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: We’ll start with Topic T1 in a minute … #cancersm |
 | Sarika Jain @drjainsp I am a molecular pathologist and a hematopathologist #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TimAllenMDJD: T1: T1: What is a biomarker and how is it identified? #cancersm |
| Amanda Narod @AmandaBinDC RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Liz Salmi @TheLizArmy @theNCI Nice to see @theNCI in the house! Tagging @NIHBrainTumor because they are the #BTSM homies. 😎 #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T1: T1: What is a biomarker and how is it identified? #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T1: T1: What is a biomarker and how is it identified? #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @TimAllenMDJD Is this a quiz? Or a lecture? #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T1: There are lots of “biomarkers” of cancer, e.g., obesity is a prognostic biomarker for certain cancers. This chat focuses specifically on molecular biomarkers of cancer. Molecular biomarkers of cancer are identified by pathologists using laboratory testing. #cancersm |
| National Cancer Institute @theNCI T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Pub Health Monitor @monitor_PH RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Alicia C. Staley @stales RT @TimAllenMDJD: T1: What is a biomarker and how is it identified? #cancersm #cancersm |
| Janet Freeman-Daily @JFreemanDaily T1: Holding my breath waiting for all the pathologists to answer ... #CANCERSM |
 | Hillary (Stires) Andrews, PhD @HillStirSci I’m Hillary! A frequenter of #bcsm, past breast cancer research scientist, currently working in health care policy. #cancersm |
| #LCSM Chat @lcsmchat Both? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It's a discussion! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
 | Anna Vioral (Gavin) @AnnaVioral RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher T1- Someone tell me what a biomarker is! #MMSM #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: It's a discussion! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson NIEHS: Biomarkers https://t.co/cNuwLouCPJ #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Bob Steele @steele_bob RT @pfanderson: Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T1: T1: There are lots of “biomarkers” of cancer, e.g., obesity is a prognostic biomarker for certain cancers. This chat focuses specifically on molecular biomarkers of cancer. Molecular biomarkers of cancer are identified by pathologists using laboratory testing. #cancersm |
 | Henning Willers, MD @HenningWillers @theNCI T1 anything can be a biomarker. Does not have to be a molecule. #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: NIEHS: NIEHS: Biomarkers https://t.co/cNuwLouCPJ #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson NCI Dictionary of Cancer Terms - biomarker https://t.co/rVcUwuvJ4d "A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease... Also called molecular marker and signature molecule." #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @theNCI T1 anything can be a biomarker. Does not have to be a molecule. #cancersm |
| National Cancer Institute @theNCI T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Christina Lizaso @btrfly12 RT @pfanderson: Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| #LCSM Chat @lcsmchat RT @pfanderson: Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| Pub Health Monitor @monitor_PH RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| #LCSM Chat @lcsmchat RT @pfanderson: NIEHS: NIEHS: Biomarkers https://t.co/cNuwLouCPJ #CancerSM |
| Bob Steele @steele_bob RT @pfanderson: NIEHS: NIEHS: Biomarkers https://t.co/cNuwLouCPJ #CancerSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @theNCI T1 anything can be a biomarker. Does not have to be a molecule. #cancersm |
| Christina Lizaso @btrfly12 RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| PF Anderson @pfanderson@disabled.social @pfanderson FDA: BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE https://t.co/Ua6gPOZevl #CancerSM |
| #LCSM Chat @lcsmchat RT @pfanderson: NCI Dictionary of Cancer Terms - biomarker https://t.co/rVcUwuvJ4d "A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease... Also called molecular marker and signature molecule." #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @theNCI T1 anything can be a biomarker. Does not have to be a molecule. #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: NCI Dictionary of Cancer Terms - biomarker https://t.co/rVcUwuvJ4d "A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease... Also called molecular marker and signature molecule." #CancerSM |
| National Cancer Institute @theNCI T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/Ndpiy1XWlp #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: FDA: BIOMARKER TERMINOLOGY: FDA: BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE https://t.co/Ua6gPOZevl #CancerSM |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T1: T1: There are lots of “biomarkers” of cancer, e.g., obesity is a prognostic biomarker for certain cancers. This chat focuses specifically on molecular biomarkers of cancer. Molecular biomarkers of cancer are identified by pathologists using laboratory testing. #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: FDA: BIOMARKER TERMINOLOGY: FDA: BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE https://t.co/Ua6gPOZevl #CancerSM |
| Matthew Katz, MD 🟦 @subatomicdoc RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| #LCSM Chat @lcsmchat RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Bob Steele @steele_bob RT @HenningWillers: @theNCI T1 anything can be a biomarker. Does not have to be a molecule. #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher T1- Is fever is a biomarker of infection? #cancersm |
| Alicia C. Staley @stales RT @pfanderson: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/GmeVQy9VGa #CancerSM |
| #LCSM Chat @lcsmchat RT @pfanderson: FDA: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/Ndpiy1XWlp #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: FDA: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/Ndpiy1XWlp #CancerSM |
| Liz Salmi @TheLizArmy RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T1: T1: There are lots of “biomarkers” of cancer, e.g., obesity is a prognostic biomarker for certain cancers. This chat focuses specifically on molecular biomarkers of cancer. Molecular biomarkers of cancer are identified by pathologists using laboratory testing. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Bob Steele @steele_bob RT @pfanderson: FDA: BIOMARKER TERMINOLOGY: FDA: BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE https://t.co/Ua6gPOZevl #CancerSM |
| Alicia C. Staley @stales RT @pfanderson: FDA: BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE https://t.co/7KTEDxPF7d #CancerSM |
| National Cancer Institute @theNCI T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| Alicia C. Staley @stales RT @pfanderson: NIEHS: Biomarkers https://t.co/xadnCHehR1 #CancerSM |
| Pub Health Monitor @monitor_PH RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: T1- Is fever is a biomarker of infection? #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: T1- Is fever is a biomarker of infection? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: RT @pfanderson: FDA: RT @pfanderson: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/GmeVQy9VGa #CancerSM |
| #LCSM Chat @lcsmchat RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @stales: RT @pfanderson: FDA: RT @pfanderson: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/GmeVQy9VGa #CancerSM |
| Christina Lizaso @btrfly12 RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Alicia C. Staley @stales @MyelomaTeacher I"m learning tonight too! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @lcsmchat LOL! I'm seeing great stuff being shared from a lot of different directions. Going to be a great hour! #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: RT @pfanderson: NIEHS: RT @pfanderson: NIEHS: Biomarkers https://t.co/xadnCHehR1 #CancerSM |
| Henning Willers, MD @HenningWillers T1 A biomarker can be predictive of treatment response or prognostic for disease course independent of treatment (ok that was not really the question) #cancersm |
| Matthew Steliga MD FACS @SteligaMD T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| Bob Steele @steele_bob RT @pfanderson: @lcsmchat LOL! I'm seeing great stuff being shared from a lot of different directions. Going to be a great hour! #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Sarika Jain @drjainsp T1: A Biomarker also tells you if you will respond to a treatment and also treatment response #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: @MyelomaTeacher I"m learning tonight too! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @lcsmchat LOL! I'm seeing great stuff being shared from a lot of different directions. Going to be a great hour! #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @pfanderson: FDA: FDA: What Are Biomarkers and Why Are They Important? Transcript https://t.co/Ndpiy1XWlp #CancerSM |
| Bob Steele @steele_bob RT @SteligaMD: T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| #LCSM Chat @lcsmchat RT @pfanderson: @lcsmchat LOL! I'm seeing great stuff being shared from a lot of different directions. Going to be a great hour! #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: T1 A biomarker can be predictive of treatment response or prognostic for disease course independent of treatment (ok that was not really the question) #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: T1 A biomarker can be predictive of treatment response or prognostic for disease course independent of treatment (ok that was not really the question) #cancersm |
| #LCSM Chat @lcsmchat RT @SteligaMD: T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @SteligaMD: T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T1: T1: A Biomarker also tells you if you will respond to a treatment and also treatment response #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T1: T1: A Biomarker also tells you if you will respond to a treatment and also treatment response #cancersm |
| Amanda Narod @AmandaBinDC T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @HenningWillers: T1 A biomarker can be predictive of treatment response or prognostic for disease course independent of treatment (ok that was not really the question) #cancersm |
| Liz Salmi @TheLizArmy @TimAllenMDJD So I am guessing, for us brain tumor people, our biomarkers are found in the TISSUE of the tumor after it is removed or biopsied... ? #cancersm #btsm |
| Israh Akhtar Khan @israhkhan #CANCERSM- These are the various faces of this deadly disease a) breast cancer in bone b) hepatocellular carcinoma in ascitic fluid c) lung carcinoma invading blood vessel and Lung adenocarcinoma. What can we do to prevent it or are there any potential tests which can aid in Rx https://t.co/0C3ZOTqEO8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AmandaBinDC: T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
| Bob Steele @steele_bob RT @AmandaBinDC: T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @TimAllenMDJD So I am guessing, for us brain tumor people, our biomarkers are found in the TISSUE of the tumor after it is removed or biopsied... ? #cancersm #btsm |
| National Cancer Institute @theNCI T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher #cancersm This is a great slide. #MMSM #Biomarkers https://t.co/XvmjWfL296 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM- These are the various faces of this deadly disease a) breast cancer in bone b) hepatocellular carcinoma in ascitic fluid c) lung carcinoma invading blood vessel and Lung adenocarcinoma. What can we do to prevent it or are there any potential tests which can aid in Rx https://t.co/0C3ZOTqEO8 |
| Pub Health Monitor @monitor_PH RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Bob Steele @steele_bob RT @israhkhan: #CANCERSM- These are the various faces of this deadly disease a) breast cancer in bone b) hepatocellular carcinoma in ascitic fluid c) lung carcinoma invading blood vessel and Lung adenocarcinoma. What can we do to prevent it or are there any potential tests which can aid in Rx https://t.co/0C3ZOTqEO8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T2: What is biomarker testing and what is it used for? #cancersm |
 | Luciole🩵ほたる @Luciole0207 RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
 | Brenda Conaway @BLouConaway RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
 | Dee Sparacio @womenofteal Hi #CANCERSM friends, Sorry to be joining late. And trying to catch up. Dee here #gyncsm co-founder. |
| #LCSM Chat @lcsmchat RT @AmandaBinDC: T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @TimAllenMDJD So I am guessing, for us brain tumor people, our biomarkers are found in the TISSUE of the tumor after it is removed or biopsied... ? #cancersm #btsm |
| Liz Salmi @TheLizArmy @theNCI Where's @xelamb and @GCAResearch at??? This biomarker stuff has to be your jam. #btsm #cancersm |
| Alicia C. Staley @stales RT @TimAllenMDJD: T2: What is biomarker testing and what is it used for? #cancersm #cancersm |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM- These are the various faces of this deadly disease a) breast cancer in bone b) hepatocellular carcinoma in ascitic fluid c) lung carcinoma invading blood vessel and Lung adenocarcinoma. What can we do to prevent it or are there any potential tests which can aid in Rx https://t.co/0C3ZOTqEO8 |
 | Maria Triolo @MariaTriolo RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| #LCSM Chat @lcsmchat RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Alicia C. Staley @stales @womenofteal hey there! #cancersm |
| Brenda Conaway @BLouConaway RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: #cancersm This is a great slide. #MMSM #Biomarkers https://t.co/XvmjWfL296 |
| Matthew Steliga MD FACS @SteligaMD RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T2: T2: What is biomarker testing and what is it used for? #cancersm |
| Alicia C. Staley @stales @TheLizArmy hey there #cancersm |
| Bob Steele @steele_bob RT @MyelomaTeacher: #cancersm This is a great slide. #MMSM #Biomarkers https://t.co/XvmjWfL296 |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Dee Sparacio @womenofteal #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @theNCI Where's @xelamb and @GCAResearch at??? This biomarker stuff has to be your jam. #btsm #cancersm |
| National Cancer Institute @theNCI T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: Hi #CANCERSM friends, Sorry to be joining late. And trying to catch up. Dee here #gyncsm co-founder. |
| Pub Health Monitor @monitor_PH RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| Sarika Jain @drjainsp T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Welcome! #cancersm |
| Alicia C. Staley @stales RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @AmandaBinDC: T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
| Bob Steele @steele_bob RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| National Cancer Institute @theNCI T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| Dee Sparacio @womenofteal RT @stales: RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @israhkhan: #CANCERSM- These are the various faces of this deadly disease a) breast cancer in bone b) hepatocellular carcinoma in ascitic fluid c) lung carcinoma invading blood vessel and Lung adenocarcinoma. What can we do to prevent it or are there any potential tests which can aid in Rx https://t.co/0C3ZOTqEO8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T2: Molecular biomarker testing involves laboratory tests that evaluate and identify the presence, on the surface of a cancer cell for e.g. a protein, or the identification of mutations or other changes in the cancer cell genes. #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| Pub Health Monitor @monitor_PH RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| Liz Salmi @TheLizArmy @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| National Cancer Institute @theNCI T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| Jamie Holloway, PhD @jamienholloway T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| Christina Lizaso @btrfly12 RT @HenningWillers: T1 A biomarker can be predictive of treatment response or prognostic for disease course independent of treatment (ok that was not really the question) #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: T2: T2: Molecular biomarker testing involves laboratory tests that evaluate and identify the presence, on the surface of a cancer cell for e.g. a protein, or the identification of mutations or other changes in the cancer cell genes. #cancersm |
| Christina Lizaso @btrfly12 RT @SteligaMD: T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T2: T2: Molecular biomarker testing involves laboratory tests that evaluate and identify the presence, on the surface of a cancer cell for e.g. a protein, or the identification of mutations or other changes in the cancer cell genes. #cancersm |
| Jamie Holloway, PhD @jamienholloway @TheLizArmy @HenningWillers We do that in the breast cancer world, too! #cancersm |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| #LCSM Chat @lcsmchat RT @jamienholloway: T2: T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD This #cancersm |
 | CancerDotNet @CancerDotNet RT @AmandaBinDC: T1 lay friendly overview https://t.co/GnpK7bWJkm #cancersm @CancerDotNet |
 | Ginger Riley ~Eternal Optimist~ @gingerly21 RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| National Cancer Institute @theNCI T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: T2: T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| Henning Willers, MD @HenningWillers @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
 | Elite Health @ElitehealthMI RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
 | Khadijah🪐 @kfaziz RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| #LCSM Chat @lcsmchat RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: @TheLizArmy @HenningWillers We do that in the breast cancer world, too! #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @jamienholloway: T2: T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| Alicia C. Staley @stales RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Bob Steele @steele_bob RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
| Sarika Jain @drjainsp T2 An example of a diagnostic biomarker is prostate-specific antigen (PSA) used for screening of prostate cancer. An example of a therapeutic biomarker is EGFR gene testing in patients with lung cancer.#cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
 | 🌎 Sal @J1262Sal RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T2 An example of a diagnostic biomarker is prostate-specific antigen (PSA) used for screening of prostate cancer. An example of a therapeutic biomarker is EGFR gene testing in patients with lung cancer.#cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @theNCI It has been an amazing ride the past couple decades, watching noninvasive biomarker testing emerge & become refined. First predicted in the early 1900s, and they made fun of the guy then. Now we have salivary & urinary & breath analysis #CancerSM |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @drjainsp: T2 An example of a diagnostic biomarker is prostate-specific antigen (PSA) used for screening of prostate cancer. An example of a therapeutic biomarker is EGFR gene testing in patients with lung cancer.#cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T2 An example of a diagnostic biomarker is prostate-specific antigen (PSA) used for screening of prostate cancer. An example of a therapeutic biomarker is EGFR gene testing in patients with lung cancer.#cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T2: T2: What is biomarker testing and what is it used for? #cancersm |
| Liz Salmi @TheLizArmy @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
 | Sarah Temkin @temkins RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TheLizArmy @HenningWillers T1: @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| Christina Lizaso @btrfly12 RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TheLizArmy @HenningWillers T1: @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T2: T2: Molecular biomarker testing involves laboratory tests that evaluate and identify the presence, on the surface of a cancer cell for e.g. a protein, or the identification of mutations or other changes in the cancer cell genes. #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @theNCI Would the measurement of my m-protien in my blood be considered a biomarker for myeloma ? #MMSM #CancerSM |
| Israh Akhtar Khan @israhkhan #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @TimAllenMDJD T2: @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
| Henning Willers, MD @HenningWillers @drjainsp T2 interestingly PSA can also be predictive of treatment outcome and also prognostic #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @AshleySumrallMD: @TheLizArmy @HenningWillers T1: @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: @theNCI Would the measurement of my m-protien in my blood be considered a biomarker for myeloma ? #MMSM #CancerSM |
 | OPensador89 @OPensador89 RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Bob Steele @steele_bob RT @AshleySumrallMD: @TheLizArmy @HenningWillers T1: @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Already needs to be updated. Our understanding of cancer biomarkers is evolving fast! #cancersm |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @drjainsp T2 interestingly PSA can also be predictive of treatment outcome and also prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: @theNCI Would the measurement of my m-protien in my blood be considered a biomarker for myeloma ? #MMSM #CancerSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @drjainsp T2 interestingly PSA can also be predictive of treatment outcome and also prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @TimAllenMDJD T2: @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Already needs to be updated. Our understanding of cancer biomarkers is evolving fast! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities https://t.co/Q4bzv0UQoc Salivary biomarkers and proteomics: future diagnostic and clinical utilities https://t.co/Epp0cUOsdq #CancerSM |
 | Merrilee Fullerton @DrFullertonMPP RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Bob Steele @steele_bob RT @HenningWillers: @drjainsp T2 interestingly PSA can also be predictive of treatment outcome and also prognostic #cancersm |
| Merrilee Fullerton @DrFullertonMPP RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| Sarika Jain @drjainsp RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Merrilee Fullerton @DrFullertonMPP RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: Salivary Biomarkers: Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities https://t.co/Q4bzv0UQoc Salivary biomarkers and proteomics: future diagnostic and clinical utilities https://t.co/Epp0cUOsdq #CancerSM |
 | Jose Hernandez @Pharma_Mty RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
 | ♛ ℯƖ ღ @EL504_ RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Matthew Katz, MD 🟦 @subatomicdoc RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Jose Hernandez @Pharma_Mty RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
 | Dennis Keim @denniskeim RT @pfanderson: Kyle Strimbu and Jorge A. Tavel, M.D. What are Biomarkers? (2011) https://t.co/CV1ROepZnS #CancerSM |
| Jose Hernandez @Pharma_Mty RT @theNCI: T1 Tumor markers, which are a type of biomarker, have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. https://t.co/km00Uh6EWM #cancersm |
| Janet Freeman-Daily @JFreemanDaily Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Jose Hernandez @Pharma_Mty RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| National Cancer Institute @theNCI RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Jose Hernandez @Pharma_Mty RT @theNCI: T1 Cancer researchers are working to develop new biomarkers that can be used to identify cancer in its early stages, to predict the effectiveness of treatment, and to predict the chance of cancer recurrence. #CancerSM |
| Jose Hernandez @Pharma_Mty RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| National Cancer Institute @theNCI RT @TheLizArmy: @TimAllenMDJD T2: @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: Salivary Biomarkers: Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities https://t.co/Q4bzv0UQoc Salivary biomarkers and proteomics: future diagnostic and clinical utilities https://t.co/Epp0cUOsdq #CancerSM |
| Jose Hernandez @Pharma_Mty RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| Jose Hernandez @Pharma_Mty RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Jose Hernandez @Pharma_Mty RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Dennis Keim @denniskeim RT @SteligaMD: T1 basic info on Wikipedia: https://t.co/CfEcQ77LCv. #cancersm https://t.co/4TWuSniPGP |
| Liz Salmi @TheLizArmy @TimAllenMDJD In 2016 @WHO released a NEW classification of CNS tumors (central nervous system) related to "new" knowledge about biomarkers. This new classification system kind of rocked the brain tumor world and it was really exciting for the #neuropath community. #btsm #cancersm |
| National Cancer Institute @theNCI RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
 | Deb Smith 🌻🟧 @debsmithbeach Deb from NH here, sorry to be late. #cancersm |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @TimAllenMDJD In 2016 @WHO released a NEW classification of CNS tumors (central nervous system) related to "new" knowledge about biomarkers. This new classification system kind of rocked the brain tumor world and it was really exciting for the #neuropath community. #btsm #cancersm |
| National Cancer Institute @theNCI RT @jamienholloway: T2: T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TheLizArmy @TimAllenMDJD Except there are places that STILL don’t routinely check #MGMT & #IDH in glioma #btsm #cancersm |
 | Vin @wakeup_vin RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @TimAllenMDJD In 2016 @WHO released a NEW classification of CNS tumors (central nervous system) related to "new" knowledge about biomarkers. This new classification system kind of rocked the brain tumor world and it was really exciting for the #neuropath community. #btsm #cancersm |
 | HF. @Hfahad53 RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Dee Sparacio @womenofteal @drjainsp And CA-125 is used as a biomarker to measure response to treatment for many women with #ovca #gyncsm #CANCERSM |
| PF Anderson @pfanderson@disabled.social @pfanderson @JFreemanDaily @theNCI Even breath! >> VOC breath biomarkers in lung cancer (2016) https://t.co/TmvUTPyxkp Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening (2015) https://t.co/ccpsi93wS2 #CancerSM |
| Dee Sparacio @womenofteal RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Liz Salmi @TheLizArmy @AshleySumrallMD @HenningWillers Yes! I just tweeted that! LOL Use #cancersm for tonight's chat. ;) |
| Dennis Keim @denniskeim RT @drjainsp: T2 Molecular biomarker tests are generally of three types of biomarkers: T2 Molecular biomarker tests are generally of three types of biomarkers: diagnostic, therapeutic, prognostic #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Welcome! #cancersm |
| Jose Hernandez @Pharma_Mty RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TheLizArmy @TimAllenMDJD Except there are places that STILL don’t routinely check #MGMT & #IDH in glioma #btsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @JFreemanDaily @theNCI Even breath! >> VOC breath biomarkers in lung cancer (2016) https://t.co/TmvUTPyxkp Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening (2015) https://t.co/ccpsi93wS2 #CancerSM |
| #LCSM Chat @lcsmchat RT @womenofteal: @drjainsp And CA-125 is used as a biomarker to measure response to treatment for many women with #ovca #gyncsm #CANCERSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: @drjainsp And CA-125 is used as a biomarker to measure response to treatment for many women with #ovca #gyncsm #CANCERSM |
| #LCSM Chat @lcsmchat RT @pfanderson: @JFreemanDaily @theNCI Even breath! >> VOC breath biomarkers in lung cancer (2016) https://t.co/TmvUTPyxkp Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening (2015) https://t.co/ccpsi93wS2 #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TheLizArmy @TimAllenMDJD Except there are places that STILL don’t routinely check #MGMT & #IDH in glioma #btsm #cancersm |
| Vin @wakeup_vin RT @TheLizArmy: @TimAllenMDJD T2: @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
| Bob Steele @steele_bob RT @AshleySumrallMD: @TheLizArmy @TimAllenMDJD Except there are places that STILL don’t routinely check #MGMT & #IDH in glioma #btsm #cancersm |
| HF. @Hfahad53 RT @TheLizArmy: @TimAllenMDJD T2: @TimAllenMDJD T2: For the brain community, our tumors are tested for biomarkers as a way of determining whether our tumor is more or less aggressive and likely to respond more favorably to various treatments. Treatment decisions are based on biomarkers. #btsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @AshleySumrallMD @HenningWillers Yes! I just tweeted that! LOL Use #cancersm for tonight's chat. ;) |
 | Andrea @BraveBosom RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Liz Salmi @TheLizArmy RT @AshleySumrallMD: @TheLizArmy @HenningWillers T1: @TheLizArmy @HenningWillers T1: And it changed in 2016 as the WHO reclassified gliomas #btsm #cancersm https://t.co/gcDDoZ7Rqb |
| Dennis Keim @denniskeim RT @HenningWillers: @stales @drjainsp T2 there can also be normal tissue biomarkers (eg for toxicity predictions) #cancersm |
| Christina Lizaso @btrfly12 T2: Here's an overview of what is being studied for #ovariancancer Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review https://t.co/Lo7npjtVOw #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Vin @wakeup_vin RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @btrfly12: T2: T2: Here's an overview of what is being studied for #ovariancancer Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review https://t.co/Lo7npjtVOw #cancersm |
| Liz Salmi @TheLizArmy RT @AshleySumrallMD: @TheLizArmy @TimAllenMDJD Except there are places that STILL don’t routinely check #MGMT & #IDH in glioma #btsm #cancersm |
| Andrea @BraveBosom RT @btrfly12: T2: T2: Here's an overview of what is being studied for #ovariancancer Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review https://t.co/Lo7npjtVOw #cancersm |
| National Cancer Institute @theNCI RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Christina Lizaso @btrfly12 RT @TheLizArmy: @TimAllenMDJD In 2016 @WHO released a NEW classification of CNS tumors (central nervous system) related to "new" knowledge about biomarkers. This new classification system kind of rocked the brain tumor world and it was really exciting for the #neuropath community. #btsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @TheLizArmy @HenningWillers That's amazing. Many folk I know with childhood trauma introduce themselves with their ACE score, but psych professionals I know have trouble believing this happens. I bet the docs are surprised. #CancerSM |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Dennis Keim @denniskeim RT @israhkhan: #CANCERSM While the traditional breast carcinoma prognostic markers ER, PR, Her 2 neu predicts whether a patient will need hormonal therapy or chemotherapy or Herceptin, more recently in April 2019, immunotherapy has been approved by FDA in triple negative breast ca patients https://t.co/qurV1a4y3i |
| Dee Sparacio @womenofteal #gyncsm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @TheLizArmy @HenningWillers That's amazing. Many folk I know with childhood trauma introduce themselves with their ACE score, but psych professionals I know have trouble believing this happens. I bet the docs are surprised. #CancerSM |
| Dennis Keim @denniskeim RT @HenningWillers: @drjainsp T2 interestingly PSA can also be predictive of treatment outcome and also prognostic #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T3: What treatment options can be identified through biomarker testing? #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Dennis Keim @denniskeim RT @TimAllenMDJD: Already needs to be updated. Our understanding of cancer biomarkers is evolving fast! #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Liz Salmi @TheLizArmy Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| #LCSM Chat @lcsmchat RT @btrfly12: T2: T2: Here's an overview of what is being studied for #ovariancancer Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review https://t.co/Lo7npjtVOw #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: @TheLizArmy @HenningWillers That's amazing. Many folk I know with childhood trauma introduce themselves with their ACE score, but psych professionals I know have trouble believing this happens. I bet the docs are surprised. #CancerSM |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher #MMSM Biomarkers |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @btrfly12: T2: T2: Here's an overview of what is being studied for #ovariancancer Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review https://t.co/Lo7npjtVOw #cancersm |
| Dee Sparacio @womenofteal RT @TimAllenMDJD: T3: T3: What treatment options can be identified through biomarker testing? #cancersm |
| Liz Salmi @TheLizArmy RT @TimAllenMDJD: Already needs to be updated. Our understanding of cancer biomarkers is evolving fast! #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T3: T3: What treatment options can be identified through biomarker testing? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| National Cancer Institute @theNCI T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Henning Willers, MD @HenningWillers RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| #LCSM Chat @lcsmchat RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T3: T3: What treatment options can be identified through biomarker testing? #cancersm |
| Christina Lizaso @btrfly12 RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
 | Med Peds Hospitalist @medpedshosp RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Andrea @BraveBosom Hi! Taking a break from vacation to say hello TY for organizing this combined chat. I am here from #BRCA community 👏 #cancersm. |
| Dennis Keim @denniskeim RT @womenofteal: @drjainsp And CA-125 is used as a biomarker to measure response to treatment for many women with #ovca #gyncsm #CANCERSM |
| Janet Freeman-Daily @JFreemanDaily RT @pfanderson: @JFreemanDaily @theNCI Even breath! >> VOC breath biomarkers in lung cancer (2016) https://t.co/TmvUTPyxkp Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening (2015) https://t.co/ccpsi93wS2 #CancerSM |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T3: T3: What treatment options can be identified through biomarker testing? #cancersm |
| National Cancer Institute @theNCI T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BraveBosom: Hi! Taking a break from vacation to say hello TY for organizing this combined chat. I am here from #BRCA community 👏 #cancersm. |
| Liz Salmi @TheLizArmy RT @AshleySumrallMD: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
 | spartychemist @spartychemist Biomarkers are indicators that are used to predict or diagnose condition.. in blood cancer patients .presence of certain dna or rna in blood |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
| National Cancer Institute @theNCI T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
 | α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
| Pub Health Monitor @monitor_PH RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Dee Sparacio @womenofteal #gyncsm |
| PF Anderson @pfanderson@disabled.social @pfanderson @TimAllenMDJD I'm curious about the balance between biomarkers and genome for informing treatment decisions and planning #CancerSM |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @TimAllenMDJD Can prognostic biomarkers be a group of biomarkers that stratify for risk instead of just 1 biomarker? #MMSM #CancerSM |
| #LCSM Chat @lcsmchat RT @theNCI: T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
 | Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TimAllenMDJD T3: identifying #NTRK fusion in #glioma (est 1% of gliomas) opens up avenues for 2 therapies #btsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @TimAllenMDJD I'm curious about the balance between biomarkers and genome for informing treatment decisions and planning #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: @TimAllenMDJD Can prognostic biomarkers be a group of biomarkers that stratify for risk instead of just 1 biomarker? #MMSM #CancerSM |
| Bob Steele @steele_bob Glad to report Wife has final infusion sched 7/22. But dx'd Mon with new side effect: cornea thinning. Hadn't heard of that one. #cancersm |
| Henning Willers, MD @HenningWillers T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T3 In breast cancer, testing tumors for estrogen and progesterone receptors and the HER2 protein can help doctors help determine whether treatment with hormone therapy or some targeted therapies is appropriate. #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Dee Sparacio @womenofteal @pfanderson @TimAllenMDJD great question. #cancersm |
 | c0nc0rdance @c0nc0rdance #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| Dennis Keim @denniskeim Greetings. Checking in bit late too but catching up. Another #bcsm peep. Interesting chat tonight. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: identifying #NTRK fusion in #glioma (est 1% of gliomas) opens up avenues for 2 therapies #btsm #cancersm |
| National Cancer Institute @theNCI T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| #LCSM Chat @lcsmchat RT @pfanderson: @TimAllenMDJD I'm curious about the balance between biomarkers and genome for informing treatment decisions and planning #CancerSM |
| Pub Health Monitor @monitor_PH RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: @TimAllenMDJD Can prognostic biomarkers be a group of biomarkers that stratify for risk instead of just 1 biomarker? #MMSM #CancerSM |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: identifying #NTRK fusion in #glioma (est 1% of gliomas) opens up avenues for 2 therapies #btsm #cancersm |
 | Laronica Conway @louisianagirl91 Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| #LCSM Chat @lcsmchat RT @steele_bob: Glad to report Wife has final infusion sched 7/22. But dx'd Mon with new side effect: Glad to report Wife has final infusion sched 7/22. But dx'd Mon with new side effect: cornea thinning. Hadn't heard of that one. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @AshleySumrallMD: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| Israh Akhtar Khan @israhkhan #cancersm Other well known diagnostic biomarkers are AFP for hepatocellular carcinoma, CA19-9 for pancreatic Ca, CEA for colo-rectal Ca, HCG for choriocarcinoma |
| Henning Willers, MD @HenningWillers T3 often overlooked, in #radonc tumor size/volume determines radiation dose and whether chemotherapy should be added #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TimAllenMDJD T3: and... finding #H3K27m mutations opens the door to try drugs like #ONC201 (as seen at #ASCO19) #cancersm |
 | LIU Dawei, M.D., Ph.D. @liudawei05329 RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @spartychemist Thanks. So my m-spike is a biomarker of my cancer. #MMSM #cancerSM |
| Bob Steele @steele_bob RT @louisianagirl91: Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| #LCSM Chat @lcsmchat RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| Henning Willers, MD @HenningWillers RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Liz Salmi @TheLizArmy @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD My best to your wife. #cancersm |
| Jamie Holloway, PhD @jamienholloway T3: SO MANY OPTIONS can be identified through biomarkers. Hormone therapy, immunotherapy, targeted kinase inhibitors, antibodies like herceptin... They can also point to clinical trials #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: @spartychemist Thanks. So my m-spike is a biomarker of my cancer. #MMSM #cancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: and... finding #H3K27m mutations opens the door to try drugs like #ONC201 (as seen at #ASCO19) #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @womenofteal @TimAllenMDJD We hear a lot these days about analyzing tumor genomes for resistant cases, and we hear about the rare miracles, but ... there are a lot of non-miracles, and it's still really new. #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: T3 often overlooked, in #radonc tumor size/volume determines radiation dose and whether chemotherapy should be added #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #cancersm Other well known diagnostic biomarkers are AFP for hepatocellular carcinoma, CA19-9 for pancreatic Ca, CEA for colo-rectal Ca, HCG for choriocarcinoma |
| Janet Freeman-Daily @JFreemanDaily @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @louisianagirl91: Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Andrea @BraveBosom @womenofteal @drjainsp CA125 has a ton of false positives/ can be inaccurate. I have had quite a few scares. Hope for better biomarkers in the future for #brca. #cancersm |
| Laronica Conway @louisianagirl91 👋🏾👋🏾 Hey Dr. Tim! Late and lurking! 👀 🤗 #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @denniskeim: Greetings. Checking in bit late too but catching up. Another #bcsm peep. Interesting chat tonight. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| #LCSM Chat @lcsmchat RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: @pfanderson @TimAllenMDJD great question. #cancersm |
| Dee Sparacio @womenofteal RT @israhkhan: #cancersm Other well known diagnostic biomarkers are AFP for hepatocellular carcinoma, CA19-9 for pancreatic Ca, CEA for colo-rectal Ca, HCG for choriocarcinoma |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| Liz Salmi @TheLizArmy RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| National Cancer Institute @theNCI RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @israhkhan: #cancersm Other well known diagnostic biomarkers are AFP for hepatocellular carcinoma, CA19-9 for pancreatic Ca, CEA for colo-rectal Ca, HCG for choriocarcinoma |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @womenofteal @TimAllenMDJD We hear a lot these days about analyzing tumor genomes for resistant cases, and we hear about the rare miracles, but ... there are a lot of non-miracles, and it's still really new. #CancerSM |
| #LCSM Chat @lcsmchat RT @israhkhan: #cancersm Other well known diagnostic biomarkers are AFP for hepatocellular carcinoma, CA19-9 for pancreatic Ca, CEA for colo-rectal Ca, HCG for choriocarcinoma |
| c0nc0rdance @c0nc0rdance RT @theNCI: T1 Tumor markers provide information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment: https://t.co/km00Uh6EWM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: T3 often overlooked, in #radonc tumor size/volume determines radiation dose and whether chemotherapy should be added #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: and... finding #H3K27m mutations opens the door to try drugs like #ONC201 (as seen at #ASCO19) #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: @spartychemist Thanks. So my m-spike is a biomarker of my cancer. #MMSM #cancerSM |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
 | Natick Bobcat @NatickBobCat RT @TimAllenMDJD: Welcome to #cancersm Chat! This hour all the cancer hashtag communities come together to visit, learn, & share perspectives from our own cancer communities. Our topic is “Basics of Biomarker Testing” |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: T3: T3: SO MANY OPTIONS can be identified through biomarkers. Hormone therapy, immunotherapy, targeted kinase inhibitors, antibodies like herceptin... They can also point to clinical trials #cancersm |
| #LCSM Chat @lcsmchat RT @jamienholloway: T3: T3: SO MANY OPTIONS can be identified through biomarkers. Hormone therapy, immunotherapy, targeted kinase inhibitors, antibodies like herceptin... They can also point to clinical trials #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T2 Tumor tissue markers, which are found in actual tumors, are used to diagnose, stage, and/or classify cancer, to estimate prognosis, and to select an appropriate treatment (e.g., treatment with a targeted therapy). #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: @womenofteal @TimAllenMDJD We hear a lot these days about analyzing tumor genomes for resistant cases, and we hear about the rare miracles, but ... there are a lot of non-miracles, and it's still really new. #CancerSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| Christina Lizaso @btrfly12 @steele_bob We were just hearing about eye-related side effects on last night's #gyncsm chat about maintenance therapies. #cancersm |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T2 Circulating tumor markers, which can be found in the blood, urine, stool, or other bodily fluids of some patients with cancer, are used, for example, to estimate prognosis and to assess the response to treatment. #CancerSM |
| #LCSM Chat @lcsmchat RT @BraveBosom: @womenofteal @drjainsp CA125 has a ton of false positives/ can be inaccurate. I have had quite a few scares. Hope for better biomarkers in the future for #brca. #cancersm |
| Israh Akhtar Khan @israhkhan #CANCERSM advanced lung cancer patients may be responsive to immunotherapy (keytruda)if the tumor cells are PDL1 positive |
| c0nc0rdance @c0nc0rdance RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T2 There are two main types of tumor markers that have different uses in cancer care: T2 There are two main types of tumor markers that have different uses in cancer care: circulating tumor markers and tumor tissue markers. https://t.co/NfmRcRa1I1 #cancersm |
| Christina Lizaso @btrfly12 RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| #LCSM Chat @lcsmchat RT @btrfly12: @steele_bob We were just hearing about eye-related side effects on last night's #gyncsm chat about maintenance therapies. #cancersm |
 | eduardo cervera @emircervera RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @theNCI In myeloma the expression of BCMA is used as a biomarker for CAR-T cell therapy #MMSM #cancerSM |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM advanced lung cancer patients may be responsive to immunotherapy (keytruda)if the tumor cells are PDL1 positive |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy, @louisianagirl91! Glad you're here at #cancersm |
| c0nc0rdance @c0nc0rdance RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| National Cancer Institute @theNCI RT @TimAllenMDJD: T3: T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| Dennis Keim @denniskeim RT @israhkhan: #CANCERSM advanced lung cancer patients may be responsive to immunotherapy (keytruda)if the tumor cells are PDL1 positive |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM advanced lung cancer patients may be responsive to immunotherapy (keytruda)if the tumor cells are PDL1 positive |
 | We Dietitians @WeDietitians RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @btrfly12: @steele_bob We were just hearing about eye-related side effects on last night's #gyncsm chat about maintenance therapies. #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TimAllenMDJD: T3: T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BraveBosom: @womenofteal @drjainsp CA125 has a ton of false positives/ can be inaccurate. I have had quite a few scares. Hope for better biomarkers in the future for #brca. #cancersm |
| Dennis Keim @denniskeim RT @MyelomaTeacher: @theNCI In myeloma the expression of BCMA is used as a biomarker for CAR-T cell therapy #MMSM #cancerSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T3: T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: @theNCI In myeloma the expression of BCMA is used as a biomarker for CAR-T cell therapy #MMSM #cancerSM |
| Henning Willers, MD @HenningWillers T3 are there any biomarkers that determine choice of surgery, for or against ? #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
 | David Veyna @DavidVeyna RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
 | Frufruit @_lulyf RT @TimAllenMDJD: T3: T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: @theNCI In myeloma the expression of BCMA is used as a biomarker for CAR-T cell therapy #MMSM #cancerSM |
| Liz Salmi @TheLizArmy @TimAllenMDJD Would it be fair to say "biomarkers are the new pathology?" Or is it a teamwork between the two? #btsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @BraveBosom @womenofteal @drjainsp Agree! That's one of the messy ones (CA125), and that it is so inconsistent directly connects with lack of testing and unwillingness to pursue costly invasive explorations for #OvCa and some other #GynCSM #CancerSM |
| Dee Sparacio @womenofteal @BraveBosom @drjainsp Yes we need a better biomarker or set of biomarkers to screen for OC. It is not a good marker for me either . #gyncsm #cancersm |
| Jamie Holloway, PhD @jamienholloway RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| #LCSM Chat @lcsmchat RT @HenningWillers: T3 are there any biomarkers that determine choice of surgery, for or against ? #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T3: T3: Therapeutic molecular biomarker tests identify a therapeutic target for which there is a currently available drug. #cancersm |
| Christina Lizaso @btrfly12 RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @TimAllenMDJD Would it be fair to say "biomarkers are the new pathology?" Or is it a teamwork between the two? #btsm #cancersm |
| Liz Salmi @TheLizArmy @btrfly12 @steele_bob EYE-RELATED SIDE EFFECTS? Wow. #cancersm |
| Janet Freeman-Daily @JFreemanDaily Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: @BraveBosom @womenofteal @drjainsp Agree! That's one of the messy ones (CA125), and that it is so inconsistent directly connects with lack of testing and unwillingness to pursue costly invasive explorations for #OvCa and some other #GynCSM #CancerSM |
| Christina Lizaso @btrfly12 RT @jamienholloway: T3: T3: SO MANY OPTIONS can be identified through biomarkers. Hormone therapy, immunotherapy, targeted kinase inhibitors, antibodies like herceptin... They can also point to clinical trials #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: @BraveBosom @drjainsp Yes we need a better biomarker or set of biomarkers to screen for OC. It is not a good marker for me either . #gyncsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @BraveBosom @womenofteal @drjainsp Agree! That's one of the messy ones (CA125), and that it is so inconsistent directly connects with lack of testing and unwillingness to pursue costly invasive explorations for #OvCa and some other #GynCSM #CancerSM |
| Bob Steele @steele_bob RT @TheLizArmy: @TimAllenMDJD Would it be fair to say "biomarkers are the new pathology?" Or is it a teamwork between the two? #btsm #cancersm |
| Andrea @BraveBosom RT @womenofteal: @BraveBosom @drjainsp Yes we need a better biomarker or set of biomarkers to screen for OC. It is not a good marker for me either . #gyncsm #cancersm |
| Sarika Jain @drjainsp RT @israhkhan: #CANCERSM advanced lung cancer patients may be responsive to immunotherapy (keytruda)if the tumor cells are PDL1 positive |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
 | Sabin Motwani @sabinbmotwanimd Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| Christina Lizaso @btrfly12 RT @BraveBosom: @womenofteal @drjainsp CA125 has a ton of false positives/ can be inaccurate. I have had quite a few scares. Hope for better biomarkers in the future for #brca. #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Dee Sparacio @womenofteal RT @TheLizArmy: @TimAllenMDJD Would it be fair to say "biomarkers are the new pathology?" Or is it a teamwork between the two? #btsm #cancersm |
| Loves Mashed Potatoes @glostaMAssachu RT @pfanderson: @womenofteal @TimAllenMDJD We hear a lot these days about analyzing tumor genomes for resistant cases, and we hear about the rare miracles, but ... there are a lot of non-miracles, and it's still really new. #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Fair enough! #cancersm |
| Andrea @BraveBosom RT @pfanderson: @BraveBosom @womenofteal @drjainsp Agree! That's one of the messy ones (CA125), and that it is so inconsistent directly connects with lack of testing and unwillingness to pursue costly invasive explorations for #OvCa and some other #GynCSM #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: T3 are there any biomarkers that determine choice of surgery, for or against ? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @HenningWillers Do chromogranin/synaptophysin count to help in lung cancer? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @btrfly12 @steele_bob EYE-RELATED SIDE EFFECTS? Wow. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Jamie Holloway, PhD @jamienholloway Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @HenningWillers Do chromogranin/synaptophysin count to help in lung cancer? #cancersm |
| Christina Lizaso @btrfly12 RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| Liz Salmi @TheLizArmy RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Dennis Keim @denniskeim RT @subatomicdoc: @HenningWillers Do chromogranin/synaptophysin count to help in lung cancer? #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| #LCSM Chat @lcsmchat RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @HenningWillers Do chromogranin/synaptophysin count to help in lung cancer? #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Dee Sparacio @womenofteal RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| National Cancer Institute @theNCI RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Dennis Keim @denniskeim RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| Sarika Jain @drjainsp T3: On the other hand, if a patient's biomarker testing does not show that that patient's cancer contains that therapeutic target on the cancer cell, then treating that patient with the corresponding, often expensive drug would provide no therapeutic benefit. #cancersm |
| Dee Sparacio @womenofteal RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Henning Willers, MD @HenningWillers @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Matthew Steliga MD FACS @SteligaMD RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Sarika Jain @drjainsp T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
| Dee Sparacio @womenofteal RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @HenningWillers @TimAllenMDJD In the future, I hope we have this to help w managing various #brainmets #btsm #cancersm (current ex: melanoma) |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| Bob Steele @steele_bob RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T3: T3: On the other hand, if a patient's biomarker testing does not show that that patient's cancer contains that therapeutic target on the cancer cell, then treating that patient with the corresponding, often expensive drug would provide no therapeutic benefit. #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T3: T3: On the other hand, if a patient's biomarker testing does not show that that patient's cancer contains that therapeutic target on the cancer cell, then treating that patient with the corresponding, often expensive drug would provide no therapeutic benefit. #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
 | Mohamad Amirul Zikri 🇲🇾🏴 @AmirulZickery RT @jamienholloway: T2: T2: In cancer, biomarker testing is analysis of DNA, RNA, or proteins that provide info about the diagnosis, prognosis, or are predictive for response to treatment #CANCERSM |
| National Cancer Institute @theNCI RT @drjainsp: T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
 | cunmarket.com @ebscbwi RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Jamie Holloway, PhD @jamienholloway I wouldn't go quite that far, but there are increasingly more treatment options that are more dependent on biomarker expression than tumor histology. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @HenningWillers @TimAllenMDJD In the future, I hope we have this to help w managing various #brainmets #btsm #cancersm (current ex: melanoma) |
| Mohamad Amirul Zikri 🇲🇾🏴 @AmirulZickery RT @theNCI: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: T2 If you are interested in learning more about tumor markers, please see our expert-reviewed fact sheet on these biomarkers: https://t.co/km00Uh6EWM #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @HenningWillers @TimAllenMDJD In the future, I hope we have this to help w managing various #brainmets #btsm #cancersm (current ex: melanoma) |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Henning Willers, MD @HenningWillers @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @jamienholloway: I wouldn't go quite that far, but there are increasingly more treatment options that are more dependent on biomarker expression than tumor histology. #cancersm |
 | Amanda Haddock 🧬 @AmandaHaddock Checking in late but trying to catch up. Coming in from #btsm community.#CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: I wouldn't go quite that far, but there are increasingly more treatment options that are more dependent on biomarker expression than tumor histology. #cancersm |
| Dennis Keim @denniskeim RT @TheLizArmy: @HenningWillers T1: @HenningWillers T1: In the brain tumor community, biomarkers are how we patients introduce ourselves to each other. No longer do we talk about the types or grades (i.e. stage) of our tumors, we talk about our biomarkers. For reals. 🤓 #BTSM #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Dennis Keim @denniskeim RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Amanda Haddock 🧬 @AmandaHaddock RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Christina Lizaso @btrfly12 RT @drjainsp: T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @TheLizArmy @btrfly12 @steele_bob I wonder sometimes about general role of inflammation, which targets just about anything in the body. Sometimes treatments exacerbate underlying problems. They've known about eyes a long time > Ocular toxicity of antineoplastic agents. (1983) https://t.co/vhqn7tU9PU #CancerSM |
| Sarika Jain @drjainsp T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
| Dennis Keim @denniskeim RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| Janet Freeman-Daily @JFreemanDaily @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Laronica Conway @louisianagirl91 RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Bob Steele @steele_bob RT @drjainsp: T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: @TheLizArmy @btrfly12 @steele_bob I wonder sometimes about general role of inflammation, which targets just about anything in the body. Sometimes treatments exacerbate underlying problems. They've known about eyes a long time > Ocular toxicity of antineoplastic agents. (1983) https://t.co/vhqn7tU9PU #CancerSM |
| Israh Akhtar Khan @israhkhan #CANCERSM more recently Fibroblast growth factor receptor 3 (FGFR3) mutations have been seen to occur in low grade bladder carcinoma and like EGFR is a tyrosine kinase receptor gene |
| Christina Lizaso @btrfly12 RT @jamienholloway: I wouldn't go quite that far, but there are increasingly more treatment options that are more dependent on biomarker expression than tumor histology. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Dennis Keim @denniskeim RT @jamienholloway: T3: T3: SO MANY OPTIONS can be identified through biomarkers. Hormone therapy, immunotherapy, targeted kinase inhibitors, antibodies like herceptin... They can also point to clinical trials #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @drjainsp: T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @TheLizArmy @btrfly12 @steele_bob I wonder sometimes about general role of inflammation, which targets just about anything in the body. Sometimes treatments exacerbate underlying problems. They've known about eyes a long time > Ocular toxicity of antineoplastic agents. (1983) https://t.co/vhqn7tU9PU #CancerSM |
| Bob Steele @steele_bob RT @israhkhan: #CANCERSM more recently Fibroblast growth factor receptor 3 (FGFR3) mutations have been seen to occur in low grade bladder carcinoma and like EGFR is a tyrosine kinase receptor gene |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AmandaHaddock: Checking in late but trying to catch up. Coming in from #btsm community.#CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
| Dennis Keim @denniskeim RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM more recently Fibroblast growth factor receptor 3 (FGFR3) mutations have been seen to occur in low grade bladder carcinoma and like EGFR is a tyrosine kinase receptor gene |
| PF Anderson @pfanderson@disabled.social @pfanderson @TimAllenMDJD Well said! We need a nice little cartoon or comic to illustrate this concept. A good visual #CancerSM |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM more recently Fibroblast growth factor receptor 3 (FGFR3) mutations have been seen to occur in low grade bladder carcinoma and like EGFR is a tyrosine kinase receptor gene |
 | Julie Bonnett @Brjukala YES!!!!!!!! So patients done endure treatments that WON’T work! Just as important as pre-selecting therapy they are likely to respond to!! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @sabinbmotwanimd: Also important not only to find therapeutic biomarkers but also markers of resistance #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Sarika Jain @drjainsp T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock RT @AshleySumrallMD: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: @TimAllenMDJD T3 In #glioma, we use biomarkers as part of trial eligibilty. For ex: #MGMT status (although it is controversial) #btsm #cancersm |
| Dennis Keim @denniskeim RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @TimAllenMDJD Well said! We need a nice little cartoon or comic to illustrate this concept. A good visual #CancerSM |
| National Cancer Institute @theNCI T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @drjainsp: T3 These drugs, like all drugs, have side effects, so beyond the needless cost, it is important to not treat patients with these molecular therapies if the biomarker testing shows that the drug would not benefit the patient. #cancersm |
| Dennis Keim @denniskeim RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @jamienholloway Depends on tumor type. Look at how “breast ca” is a multitude of diseases defined by ER, PR, H2N, and now PIK3CA. #bcsm #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
| National Cancer Institute @theNCI RT @drjainsp: T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
 | José Gaxiola-López @GAXILO RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @drjainsp: T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
| Bob Steele @steele_bob RT @pfanderson: @TheLizArmy @btrfly12 @steele_bob I wonder sometimes about general role of inflammation, which targets just about anything in the body. Sometimes treatments exacerbate underlying problems. They've known about eyes a long time > Ocular toxicity of antineoplastic agents. (1983) https://t.co/vhqn7tU9PU #CancerSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| #LCSM Chat @lcsmchat RT @drjainsp: T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock @theNCI Thanks for this!! Was just wondering if something like this existed!#cancersm |
| National Cancer Institute @theNCI T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Sarika Jain @drjainsp T4 For colon cancers, RAS gene testing to guide anti-EGFR therapy. BRAF mutational testing should also be performed for prognostic information. #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Pub Health Monitor @monitor_PH RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @jamienholloway Depends on tumor type. Look at how “breast ca” is a multitude of diseases defined by ER, PR, H2N, and now PIK3CA. #bcsm #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @jamienholloway Depends on tumor type. Look at how “breast ca” is a multitude of diseases defined by ER, PR, H2N, and now PIK3CA. #bcsm #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
 | jaime rueda @Jr121014921 RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Henning Willers, MD @HenningWillers RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T4 For colon cancers, RAS gene testing to guide anti-EGFR therapy. BRAF mutational testing should also be performed for prognostic information. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AmandaHaddock: @theNCI Thanks for this!! Was just wondering if something like this existed!#cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
 | Louella Vasquez @VasquezLouella RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| #LCSM Chat @lcsmchat RT @drjainsp: T4 For colon cancers, RAS gene testing to guide anti-EGFR therapy. BRAF mutational testing should also be performed for prognostic information. #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @TimAllenMDJD In myeloma it would be great to have a liquid biopsy available instead of the painful bone marrow biopsy especially for repeat MRD testing. #CancerSM #MMSM |
| Liz Salmi @TheLizArmy @AshleySumrallMD @TimAllenMDJD We could do a whole session on this at @NeuroOnc. 😞#SNO2019 #cancersm #btsm |
| Sarika Jain @drjainsp T4 For Breast cancers, the pathologist performs testing for estrogen receptor, progesterone receptor, and HER2 by immunohistochemistry. #cancersm |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock I get asked about different tumor markers all the time. Bookmarking this list! |
| National Cancer Institute @theNCI T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| Pub Health Monitor @monitor_PH RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: @TimAllenMDJD In myeloma it would be great to have a liquid biopsy available instead of the painful bone marrow biopsy especially for repeat MRD testing. #CancerSM #MMSM |
 | Ivan Womboldt WEARS A MASK @iwomboldt RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD We could do a whole session on this at @NeuroOnc. 😞#SNO2019 #cancersm #btsm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @TimAllenMDJD Or CSF! T4 #btsm #cancersm https://t.co/4iKmHHEJXz |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T4 For Breast cancers, the pathologist performs testing for estrogen receptor, progesterone receptor, and HER2 by immunohistochemistry. #cancersm |
| Israh Akhtar Khan @israhkhan #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: @TimAllenMDJD In myeloma it would be great to have a liquid biopsy available instead of the painful bone marrow biopsy especially for repeat MRD testing. #CancerSM #MMSM |
| #LCSM Chat @lcsmchat RT @drjainsp: T4 For Breast cancers, the pathologist performs testing for estrogen receptor, progesterone receptor, and HER2 by immunohistochemistry. #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @TimAllenMDJD Or CSF! T4 #btsm #cancersm https://t.co/4iKmHHEJXz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @TimAllenMDJD Or CSF! T4 #btsm #cancersm https://t.co/4iKmHHEJXz |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
| National Cancer Institute @theNCI T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| Peggy Dennis @peggyddennis T4 Why stop on a just a few or only those actionable?Check all possible so as treatments become available new biopsy is not need. #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @theNCI It's pretty amazing these days what can be done with "it's just a blood test" #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| Christina Lizaso @btrfly12 RT @MyelomaTeacher: @TimAllenMDJD In myeloma it would be great to have a liquid biopsy available instead of the painful bone marrow biopsy especially for repeat MRD testing. #CancerSM #MMSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
| Bob Steele @steele_bob RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
 | Bora Lim, MD @naborala RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| National Cancer Institute @theNCI RT @TimAllenMDJD: T4: T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @MyelomaTeacher: @TimAllenMDJD In myeloma it would be great to have a liquid biopsy available instead of the painful bone marrow biopsy especially for repeat MRD testing. #CancerSM #MMSM |
 | Javier Jose Suarez G @JavierJSuarez RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @drjainsp: T4 For colon cancers, RAS gene testing to guide anti-EGFR therapy. BRAF mutational testing should also be performed for prognostic information. #cancersm |
| Alicia C. Staley @stales RT @TimAllenMDJD: T3: What treatment options can be identified through biomarker testing? #cancersm #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| Loves Mashed Potatoes @glostaMAssachu RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
 | Pallavi Tiwari @Pallavi_Tiwari RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| National Cancer Institute @theNCI T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Henning Willers, MD @HenningWillers @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| Andrea @BraveBosom RT @stales: RT @TimAllenMDJD: T3: RT @TimAllenMDJD: T3: What treatment options can be identified through biomarker testing? #cancersm #cancersm |
 | Aquilare @MagnusAquilare RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| Jamie Holloway, PhD @jamienholloway T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
 | Kristina Kotlus @KristinaKotlus RT @TimAllenMDJD: T4: T4: What biomarker tests should be run for which types of cancers? What is a liquid biopsy and when is useful? #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Glad you are here, @EdenLake! #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| #LCSM Chat @lcsmchat RT @peggyddennis: T4 Why stop on a just a few or only those actionable?Check all possible so as treatments become available new biopsy is not need. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: RT @TimAllenMDJD: T3: RT @TimAllenMDJD: T3: What treatment options can be identified through biomarker testing? #cancersm #cancersm |
 | Noel Del Valle @chitowncopr64 RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
 | Jacques QS ن @saveiro RT @drjainsp: T4 For colon cancers, RAS gene testing to guide anti-EGFR therapy. BRAF mutational testing should also be performed for prognostic information. #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: T4: T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| #LCSM Chat @lcsmchat RT @pfanderson: @theNCI It's pretty amazing these days what can be done with "it's just a blood test" #CancerSM |
| Sarika Jain @drjainsp RT @TimAllenMDJD: T4: T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @theNCI It's pretty amazing these days what can be done with "it's just a blood test" #CancerSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T4: T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @peggyddennis: T4 Why stop on a just a few or only those actionable?Check all possible so as treatments become available new biopsy is not need. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| #LCSM Chat @lcsmchat RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| c0nc0rdance @c0nc0rdance @TimAllenMDJD T4: A liquid biopsy is testing done in a biofluid like blood plasma, where DNA or protein from the tumor can be found. It avoids the cost and risk of surgical biopsy, and can better represent the DNA or protein makeup of diverse tumors. #CancerSM https://t.co/zQmvg33g5v |
| #LCSM Chat @lcsmchat RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
 | Teresa Hartman @thartman2u RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: A liquid biopsy is testing done in a biofluid like blood plasma, where DNA or protein from the tumor can be found. It avoids the cost and risk of surgical biopsy, and can better represent the DNA or protein makeup of diverse tumors. #CancerSM https://t.co/zQmvg33g5v |
| Sabin Motwani @sabinbmotwanimd T4 interpretation of biomarker test must be easy to interpret by pathology. Not as simple as positive or negative or methylated vs unmethylated. Eg MGMT #cancersm |
| Janet Freeman-Daily @JFreemanDaily @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Christina Lizaso @btrfly12 RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher IM still trying to understand the complexity of biomarker testing. Would FISH testing on BMB aspirate to determine risk stratification in myeloma be considered prognostic biomarker testing? #cancersm #MMSM |
| PF Anderson @pfanderson@disabled.social @pfanderson MIT Tech Review: Liquid Biopsy Fast DNA-sequencing machines are leading to simple blood tests for cancer. (2015) https://t.co/hw4kQVftKq #CancerSM |
| Henning Willers, MD @HenningWillers RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| Henning Willers, MD @HenningWillers RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: A liquid biopsy is testing done in a biofluid like blood plasma, where DNA or protein from the tumor can be found. It avoids the cost and risk of surgical biopsy, and can better represent the DNA or protein makeup of diverse tumors. #CancerSM https://t.co/zQmvg33g5v |
 | Jen Buhay, PhD 💙 @JenBuhayPhD RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| #LCSM Chat @lcsmchat RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: A liquid biopsy is testing done in a biofluid like blood plasma, where DNA or protein from the tumor can be found. It avoids the cost and risk of surgical biopsy, and can better represent the DNA or protein makeup of diverse tumors. #CancerSM https://t.co/zQmvg33g5v |
| #LCSM Chat @lcsmchat RT @sabinbmotwanimd: T4 interpretation of biomarker test must be easy to interpret by pathology. Not as simple as positive or negative or methylated vs unmethylated. Eg MGMT #cancersm |
| Christina Lizaso @btrfly12 RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| Liz Salmi @TheLizArmy @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
 | Raveena Nair @RaveenaNair3 Using blood to detect cancer #liquidbiopsies #FDSC898 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: MIT Tech Review: MIT Tech Review: Liquid Biopsy Fast DNA-sequencing machines are leading to simple blood tests for cancer. (2015) https://t.co/hw4kQVftKq #CancerSM |
| Jamie Holloway, PhD @jamienholloway @MyelomaTeacher You've got it, Cindy! #CANCERSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| National Cancer Institute @theNCI RT @drjainsp: T4 For Breast cancers, the pathologist performs testing for estrogen receptor, progesterone receptor, and HER2 by immunohistochemistry. #cancersm |
 | Armando Briz López @bisturi52 RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: IM still trying to understand the complexity of biomarker testing. Would FISH testing on BMB aspirate to determine risk stratification in myeloma be considered prognostic biomarker testing? #cancersm #MMSM |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @TimAllenMDJD: T2: T2: Diagnostic biomarkers help in the diagnosis of the cancer itself; therapeutic biomarkers help in determining whether or not a patient might respond to a molecular therapy; and prognostic biomarkers help determine the patient’s chances for long-term survival. #cancersm |
| Loves Mashed Potatoes @glostaMAssachu RT @jamienholloway: T4: T4: I love the quote about liquid biopsies-- It's like looking for a needle in a haystack. If you find a needle, it's a needle. But if you don't find the needle, it doesn't mean one's not there. A negative result always needs to be followed up by testing tissue. #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: IM still trying to understand the complexity of biomarker testing. Would FISH testing on BMB aspirate to determine risk stratification in myeloma be considered prognostic biomarker testing? #cancersm #MMSM |
| #LCSM Chat @lcsmchat RT @pfanderson: MIT Tech Review: MIT Tech Review: Liquid Biopsy Fast DNA-sequencing machines are leading to simple blood tests for cancer. (2015) https://t.co/hw4kQVftKq #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T4: T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T1 A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. #cancersm https://t.co/P7BJJJo98m |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @sabinbmotwanimd: T4 interpretation of biomarker test must be easy to interpret by pathology. Not as simple as positive or negative or methylated vs unmethylated. Eg MGMT #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
| α¢нмα∂ нαη∂σкσ | hand @achmadhandoko RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| #LCSM Chat @lcsmchat RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
| Matthew Katz, MD 🟦 @subatomicdoc What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Israh Akhtar Khan @israhkhan #CANCERSM : Adenocarcinoma of lung with leipidic pattern is a good prognosis carcinoma. Similarly Alk positive adenocarcinoma is known to occur in Asian females who are non-smokers https://t.co/086OyTmXbG |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T4: T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| Alicia C. Staley @stales RT @theNCI: The National Cancer Institute is here. Thanks for hosting this #cancersm chat on biomarkers! |
| National Cancer Institute @theNCI RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T4: T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @TimAllenMDJD: T4: T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| Alicia C. Staley @stales RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Dennis Keim @denniskeim @TheLizArmy @AshleySumrallMD @TimAllenMDJD Seems like that new and relevant tests should be standard operating procedure for checkups. I had what I presume was standard breast cancer pathology for 2013 and BRCA and Oncotype DX done but I imagine there are some new things that might be worthwhile knowing. #bcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM : #CANCERSM : Adenocarcinoma of lung with leipidic pattern is a good prognosis carcinoma. Similarly Alk positive adenocarcinoma is known to occur in Asian females who are non-smokers https://t.co/086OyTmXbG |
| Bob Steele @steele_bob RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Henning Willers, MD @HenningWillers RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @denniskeim: @TheLizArmy @AshleySumrallMD @TimAllenMDJD Seems like that new and relevant tests should be standard operating procedure for checkups. I had what I presume was standard breast cancer pathology for 2013 and BRCA and Oncotype DX done but I imagine there are some new things that might be worthwhile knowing. #bcsm #cancersm |
| Frufruit @_lulyf RT @drjainsp: T4 For Breast cancers, the pathologist performs testing for estrogen receptor, progesterone receptor, and HER2 by immunohistochemistry. #cancersm |
| Liz Salmi @TheLizArmy @AmandaHaddock @AshleySumrallMD @TimAllenMDJD Remember the hashtag, Amanda! #cancersm #btsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
| Christina Lizaso @btrfly12 @itsthebunk Waving hello Liza and thanks for all your do for patients! :) #cancersm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock RT @TheLizArmy: Great point! People facing a brain tumor--if diagnosed at a community hospital--might not be told about biomarker testing... which is absolutely CRUCIAL to our treatment. #BTSM #cancersm |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM : #CANCERSM : Adenocarcinoma of lung with leipidic pattern is a good prognosis carcinoma. Similarly Alk positive adenocarcinoma is known to occur in Asian females who are non-smokers https://t.co/086OyTmXbG |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @israhkhan: #CANCERSM : #CANCERSM : Adenocarcinoma of lung with leipidic pattern is a good prognosis carcinoma. Similarly Alk positive adenocarcinoma is known to occur in Asian females who are non-smokers https://t.co/086OyTmXbG |
 | oncomedicmexico @oncomedicmexico Biopsia líquida https://t.co/jsmZvQYM8H |
| Alicia C. Staley @stales RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD I was diagnosed with a brain tumor in 2008 when checking for biomarkers was not part of standard of care. In 2016, I asked my neuro-onc to run my tissue for the biomarkers panel. He asked, "Why would you want to know what your biomarkers are?" #btsm #cancersm https://t.co/BGY4SHbgDn |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @denniskeim: @TheLizArmy @AshleySumrallMD @TimAllenMDJD Seems like that new and relevant tests should be standard operating procedure for checkups. I had what I presume was standard breast cancer pathology for 2013 and BRCA and Oncotype DX done but I imagine there are some new things that might be worthwhile knowing. #bcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Alicia C. Staley @stales RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
 | Rachael @PollywogPrinces RT @c0nc0rdance: #CancerSM is a Twitter chat discussing the basics of biomarker testing for cancer. If it's a topic you're interested in, the participants are doing a great job of making cancer diagnostics accessible to anyone. Love that scientists/clinicians do this kind of outreach. |
| Alicia C. Staley @stales RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T5: T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
| Alicia C. Staley @stales RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: A liquid biopsy is testing done in a biofluid like blood plasma, where DNA or protein from the tumor can be found. It avoids the cost and risk of surgical biopsy, and can better represent the DNA or protein makeup of diverse tumors. #CancerSM https://t.co/zQmvg33g5v |
| PF Anderson @pfanderson@disabled.social @pfanderson @subatomicdoc Excellent question! So much we still need to learn! #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
 | Prathyusha Konda ✨ @labratprats RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @subatomicdoc Excellent question! So much we still need to learn! #CancerSM |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
 | Aaron Maestri @aaronmaestri RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
| Dee Sparacio @womenofteal RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @AshleySumrallMD @TimAllenMDJD There is some discordance in ER/PR/Her2 in breast cancer. Here is an example between the primary tumor and nodal metastases: https://t.co/MqhpcGuYfU What other diseases does it differ? #cancersm #bcsm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T5: T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @jamienholloway: Excellent point! It's just as important to know what drugs *won't* work! #cancersm |
| Jamie Holloway, PhD @jamienholloway T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| Matthew Katz, MD 🟦 @subatomicdoc RT @TimAllenMDJD: T5: T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
 | WhatFreshHello @whatfreshhello RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TimAllenMDJD: T5: T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| c0nc0rdance @c0nc0rdance @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @AshleySumrallMD @TimAllenMDJD There is some discordance in ER/PR/Her2 in breast cancer. Here is an example between the primary tumor and nodal metastases: https://t.co/MqhpcGuYfU What other diseases does it differ? #cancersm #bcsm |
| Dennis Keim @denniskeim RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| National Cancer Institute @theNCI T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T5: Molecular testing and molecular therapy has become the standard of care for many cancers. Most doctors are performing the recommended molecular testing on particular types of cancer. #cancersm |
| Pub Health Monitor @monitor_PH RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Dennis Keim @denniskeim RT @TimAllenMDJD: T5: T5: Can and should patients pursue biomarker testing for treatment options if their doctor does not offer it? #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @JFreemanDaily @peggyddennis I use the analogies of cherry picking (looking at just the most likely & essential ones to save time/cost) and apple harvesting (shaking the tree until everything falls off) #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @AshleySumrallMD @TimAllenMDJD There is some discordance in ER/PR/Her2 in breast cancer. Here is an example between the primary tumor and nodal metastases: https://t.co/MqhpcGuYfU What other diseases does it differ? #cancersm #bcsm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @subatomicdoc: @AshleySumrallMD @TimAllenMDJD There is some discordance in ER/PR/Her2 in breast cancer. Here is an example between the primary tumor and nodal metastases: https://t.co/MqhpcGuYfU What other diseases does it differ? #cancersm #bcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @israhkhan: #CANCERSM sadly not much is known about the genetics, biomarkers or prognostic indicators of this deadly cancer of the lung (small cell carcinoma ) https://t.co/EtuD0NG1Ni |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| #LCSM Chat @lcsmchat RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
| #LCSM Chat @lcsmchat RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
| Henning Willers, MD @HenningWillers @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @JFreemanDaily @peggyddennis I use the analogies of cherry picking (looking at just the most likely & essential ones to save time/cost) and apple harvesting (shaking the tree until everything falls off) #CancerSM |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| #LCSM Chat @lcsmchat RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T5: T5: Molecular testing and molecular therapy has become the standard of care for many cancers. Most doctors are performing the recommended molecular testing on particular types of cancer. #cancersm |
| Dee Sparacio @womenofteal #gyncsm |
| #LCSM Chat @lcsmchat RT @pfanderson: @JFreemanDaily @peggyddennis I use the analogies of cherry picking (looking at just the most likely & essential ones to save time/cost) and apple harvesting (shaking the tree until everything falls off) #CancerSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Janet Freeman-Daily @JFreemanDaily @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @drjainsp: T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @TimAllenMDJD: T4: T4: "Liquid biopsy" refers to molecular biomarker testing performed not on a patient's cancer tissue, but on cancer cells or cancer cell DNA or RNA that is floating in the blood stream. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T5: T5: Molecular testing and molecular therapy has become the standard of care for many cancers. Most doctors are performing the recommended molecular testing on particular types of cancer. #cancersm |
| Christina Lizaso @btrfly12 T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Bob Steele @steele_bob RT @HenningWillers: @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
 | Sushil adhikari @sus6550 RT @TimAllenMDJD: T4: T4: Liquid biopsy is used in cases where a biopsy of a patient's cancer cannot be performed because the patient is too ill to tolerate the diagnostic procedure, or where the cancer site is difficult to access with a biopsy e.g., a lesion deep inside the body. #cancersm |
| Alicia C. Staley @stales RT @TimAllenMDJD: T5: T5: Molecular testing and molecular therapy has become the standard of care for many cancers. Most doctors are performing the recommended molecular testing on particular types of cancer. #cancersm |
| Alicia C. Staley @stales RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @btrfly12: T5: T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @TimAllenMDJD: T3: T3: If the molecular biomarker testing shows that the patient's cancer contains the therapeutic target, then that patient might benefit from treatment with the corresponding drug. This is personalized medicine! #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage @jamienholloway Agreed! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Sarika Jain @drjainsp T5 The basic question to ask your doctor is "Given my diagnosis, is molecular biomarker testing is right for me?" You can read about guidelines which are specifically designed for patients at https://t.co/yyMAKwn2RK #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @btrfly12: T5: T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Dennis Keim @denniskeim RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @btrfly12 @JFreemanDaily We used to have https://t.co/vix57AVfiK for parts of this. Such a loss #CancerSM |
| #LCSM Chat @lcsmchat RT @btrfly12: T5: T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @subatomicdoc @TimAllenMDJD Colon. https://t.co/l7IWBkHDBW #cancersm |
| #LCSM Chat @lcsmchat RT @drjainsp: T5 The basic question to ask your doctor is "Given my diagnosis, is molecular biomarker testing is right for me?" You can read about guidelines which are specifically designed for patients at https://t.co/yyMAKwn2RK #cancersm |
| Israh Akhtar Khan @israhkhan #CANCERSM Personalized oncology is based on biomarkers (driver mutations), stage & histology. In lung Ca major biomarkers are : EGFR (10-15% NSCLCs), ALK (2-7%), ROS-1 (1-2%), K-ras (15-30%) are generally mutually exclusive. Cytology material are good substrates for this testing |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @drjainsp: T5 The basic question to ask your doctor is "Given my diagnosis, is molecular biomarker testing is right for me?" You can read about guidelines which are specifically designed for patients at https://t.co/yyMAKwn2RK #cancersm |
| Christina Lizaso @btrfly12 T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @drjainsp: T5 The basic question to ask your doctor is "Given my diagnosis, is molecular biomarker testing is right for me?" You can read about guidelines which are specifically designed for patients at https://t.co/yyMAKwn2RK #cancersm |
| Henning Willers, MD @HenningWillers RT @btrfly12: T5: T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @btrfly12: T5: T5: As @JFreemanDaily bought up, the NCCN guidelines are a great resource and an excellent place for patients to find out what the current recommendations are and ask questions of their doc's if there is a variance https://t.co/X5OVXPY9g6 #cancersm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DarcyBurbage: @jamienholloway Agreed! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD T5: It's always a good idea to ask your doctor about molecular testing; but given the confusion in this rapidly changing area, it may be difficult to know what to ask your doctor. Feel free to call your pathologist and discuss! #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| #LCSM Chat @lcsmchat RT @pfanderson: @btrfly12 @JFreemanDaily We used to have https://t.co/vix57AVfiK for parts of this. Such a loss #CancerSM |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD Colon. https://t.co/l7IWBkHDBW #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @drjainsp: T5 The basic question to ask your doctor is "Given my diagnosis, is molecular biomarker testing is right for me?" You can read about guidelines which are specifically designed for patients at https://t.co/yyMAKwn2RK #cancersm |
| #LCSM Chat @lcsmchat RT @israhkhan: #CANCERSM Personalized oncology is based on biomarkers (driver mutations), stage & histology. In lung Ca major biomarkers are : EGFR (10-15% NSCLCs), ALK (2-7%), ROS-1 (1-2%), K-ras (15-30%) are generally mutually exclusive. Cytology material are good substrates for this testing |
 | Adam L. Booth, MD @ALBoothMD RT @c0nc0rdance: @TimAllenMDJD T4: @TimAllenMDJD T4: Since we can do blood draws for liquid biopsy easily, it can improve the frequency with which an oncologists checks on the status of cancer treatments to detect as early as possible the emergence of resistance or recurrence #CancerSM https://t.co/0meqKJgon8 |
 | Sandra Spivey @SpiveySandra Coming late to the conversation. Any discussion about cost to patient for these tests? I was surprised to find I had a $3,000 copay *after* my cfDNA test was performed. #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock @c0nc0rdance @TimAllenMDJD T4: Are there solid mass tumors that are using liquid biopsy for diagnosis/progression information? As I understand it, it isn’t an approved clinical tool for brain tumors yet. #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: T5: T5: It's always a good idea to ask your doctor about molecular testing; but given the confusion in this rapidly changing area, it may be difficult to know what to ask your doctor. Feel free to call your pathologist and discuss! #cancersm |
| Liz Salmi @TheLizArmy RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
| Christina Lizaso @btrfly12 RT @HenningWillers: @TimAllenMDJD T5 absolutely! doctor should always point out all possible options even if not available at his/her own institution #cancersm |
| Henning Willers, MD @HenningWillers RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Adam L. Booth, MD @ALBoothMD RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Bob Steele @steele_bob RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD Colon. https://t.co/l7IWBkHDBW #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AmandaHaddock: @c0nc0rdance @TimAllenMDJD T4: @c0nc0rdance @TimAllenMDJD T4: Are there solid mass tumors that are using liquid biopsy for diagnosis/progression information? As I understand it, it isn’t an approved clinical tool for brain tumors yet. #cancersm |
| Liz Salmi @TheLizArmy RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @SpiveySandra: Coming late to the conversation. Any discussion about cost to patient for these tests? I was surprised to find I had a $3,000 copay *after* my cfDNA test was performed. #cancersm |
| Christina Lizaso @btrfly12 RT @theNCI: T5 NCI does not have guidelines for the use of tumor markers. However, some national and international organizations have guidelines for the use of tumor markers for some types of cancer: https://t.co/o85pqHZKoy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @subatomicdoc @TimAllenMDJD GI. @LevineCancer https://t.co/FzYiYlJXdN #cancersm |
| Janet Freeman-Daily @JFreemanDaily #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
 | meghna mehta @meghnamehta This is incredible. That’s why we need to have affordable liquid biopsies |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @israhkhan: #CANCERSM Personalized oncology is based on biomarkers (driver mutations), stage & histology. In lung Ca major biomarkers are : EGFR (10-15% NSCLCs), ALK (2-7%), ROS-1 (1-2%), K-ras (15-30%) are generally mutually exclusive. Cytology material are good substrates for this testing |
| Henning Willers, MD @HenningWillers @TimAllenMDJD T5 how do you call your pathologist? #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD Colon. https://t.co/l7IWBkHDBW #cancersm |
| Alicia C. Staley @stales RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @btrfly12 @JFreemanDaily We used to have https://t.co/vix57AVfiK for parts of this. Such a loss #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson @drjainsp When someone asks me about a new diagnosis, one of the first things I like to do is search for "questions to ask your doctor" "new diagnosis" [X = topic/diagnosis/disease/procedure/surgery] So often I find very helpful tips! #CancerSM #Medlibs |
| Alicia C. Staley @stales RT @israhkhan: #CANCERSM : #CANCERSM : Adenocarcinoma of lung with leipidic pattern is a good prognosis carcinoma. Similarly Alk positive adenocarcinoma is known to occur in Asian females who are non-smokers https://t.co/086OyTmXbG |
| Alicia C. Staley @stales RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD Colon. https://t.co/l7IWBkHDBW #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD GI. @LevineCancer https://t.co/FzYiYlJXdN #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @subatomicdoc @TimAllenMDJD And #melanoma. https://t.co/nQG9QlN2ff #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @AshleySumrallMD @TimAllenMDJD Cool thanks Ashley! #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @TimAllenMDJD: T5: T5: It's always a good idea to ask your doctor about molecular testing; but given the confusion in this rapidly changing area, it may be difficult to know what to ask your doctor. Feel free to call your pathologist and discuss! #cancersm |
| Alicia C. Staley @stales @subatomicdoc great question that I've always wondered about. #CancerSm |
| Alicia C. Staley @stales RT @TimAllenMDJD: T4: T4: Liquid biopsy is relatively new, and so not all laboratories perform it. This is a rapidly growing area but at this time molecular testing performed of the cancer tissue itself is better than liquid biopsy at the time of primary diagnosis. #cancersm |
| #LCSM Chat @lcsmchat RT @SpiveySandra: Coming late to the conversation. Any discussion about cost to patient for these tests? I was surprised to find I had a $3,000 copay *after* my cfDNA test was performed. #cancersm |
| Alicia C. Staley @stales RT @pfanderson: MIT Tech Review: MIT Tech Review: Liquid Biopsy Fast DNA-sequencing machines are leading to simple blood tests for cancer. (2015) https://t.co/hw4kQVftKq #CancerSM |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher I don't think myeloma has any established therapeutic biomarkers. @theMMRF MyDrug trial is trying to match certain mutations to type of therapy #MMSM https://t.co/L6kJFkEjIH #cancerSM |
| Alicia C. Staley @stales RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Alicia C. Staley @stales RT @sabinbmotwanimd: T4 interpretation of biomarker test must be easy to interpret by pathology. Not as simple as positive or negative or methylated vs unmethylated. Eg MGMT #cancersm |
| #LCSM Chat @lcsmchat RT @AmandaHaddock: @c0nc0rdance @TimAllenMDJD T4: @c0nc0rdance @TimAllenMDJD T4: Are there solid mass tumors that are using liquid biopsy for diagnosis/progression information? As I understand it, it isn’t an approved clinical tool for brain tumors yet. #cancersm |
| Liz Salmi @TheLizArmy @btrfly12 Can someone who is really great at Storify just Storify this tweet chat so I can share that Storify with everyone diagnosed with a malignancy yesterday, today and tomorrow??!!! Paging @BraveBosom. #cancersm #btsm |
| Adam L. Booth, MD @ALBoothMD RT @subatomicdoc: What about the role of WHERE we sample? Do biomarker findings have different implications if biopsy taken from the primary tumor or a site of disease spread? #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD GI. @LevineCancer https://t.co/FzYiYlJXdN #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @HenningWillers @TimAllenMDJD Exactly! Are pathologists accessible to the public? How do you find out who is "your" pathologist? #CancerSM |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: T5: T5: It's always a good idea to ask your doctor about molecular testing; but given the confusion in this rapidly changing area, it may be difficult to know what to ask your doctor. Feel free to call your pathologist and discuss! #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @TimAllenMDJD T5 how do you call your pathologist? #cancersm |
| Jamie Holloway, PhD @jamienholloway @AmandaHaddock @c0nc0rdance @TimAllenMDJD There is an FDA-approved companion diagnostic in lung cancer. But still, a negative liquid biopsy needs to reflex to tumor tissue analysis because not all tumors shed enough DNA. #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @SpiveySandra: Coming late to the conversation. Any discussion about cost to patient for these tests? I was surprised to find I had a $3,000 copay *after* my cfDNA test was performed. #cancersm |
| #LCSM Chat @lcsmchat RT @pfanderson: @HenningWillers @TimAllenMDJD Exactly! Are pathologists accessible to the public? How do you find out who is "your" pathologist? #CancerSM |
| #LCSM Chat @lcsmchat RT @pfanderson: @drjainsp When someone asks me about a new diagnosis, one of the first things I like to do is search for "questions to ask your doctor" "new diagnosis" [X = topic/diagnosis/disease/procedure/surgery] So often I find very helpful tips! #CancerSM #Medlibs |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD And #melanoma. https://t.co/nQG9QlN2ff #cancersm |
| #LCSM Chat @lcsmchat RT @MyelomaTeacher: I don't think myeloma has any established therapeutic biomarkers. @theMMRF MyDrug trial is trying to match certain mutations to type of therapy #MMSM https://t.co/L6kJFkEjIH #cancerSM |
 | Liliana Larsson MSN, RN, OCN, CCRP, TTS 🇨🇴🇺🇸 @MSN_RNLiliana RT @theNCI: T3 A number of tumor markers are currently being used for a wide range of cancer types. Here’s a list of tumor markers in common use: https://t.co/NtPLX1lStR #cancersm |
| Henning Willers, MD @HenningWillers @JFreemanDaily i have definitely trouble keeping up!! #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Get your pathology report and usually there's a phone number. If not, your hospital or clinic should be able to provide it. #cancersm |
| Dennis Keim @denniskeim RT @TheLizArmy: @AshleySumrallMD @TimAllenMDJD @NeuroOnc Before @WHO came out with the 2016 CNS reclassification, I stalked a #neuropath conference on Twitter to learn all about it... then I blogged about it. Ladies & gentle-persons: This is @TheLizArmy circa 2015. https://t.co/WKthTX0pNy #cancersm #btsm #memories |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jamienholloway: @AmandaHaddock @c0nc0rdance @TimAllenMDJD There is an FDA-approved companion diagnostic in lung cancer. But still, a negative liquid biopsy needs to reflex to tumor tissue analysis because not all tumors shed enough DNA. #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @jamienholloway: @AmandaHaddock @c0nc0rdance @TimAllenMDJD There is an FDA-approved companion diagnostic in lung cancer. But still, a negative liquid biopsy needs to reflex to tumor tissue analysis because not all tumors shed enough DNA. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @HenningWillers @TimAllenMDJD Exactly! Are pathologists accessible to the public? How do you find out who is "your" pathologist? #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TheLizArmy: @btrfly12 Can someone who is really great at Storify just Storify this tweet chat so I can share that Storify with everyone diagnosed with a malignancy yesterday, today and tomorrow??!!! Paging @BraveBosom. #cancersm #btsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @MyelomaTeacher: I don't think myeloma has any established therapeutic biomarkers. @theMMRF MyDrug trial is trying to match certain mutations to type of therapy #MMSM https://t.co/L6kJFkEjIH #cancerSM |
| #LCSM Chat @lcsmchat RT @jamienholloway: @AmandaHaddock @c0nc0rdance @TimAllenMDJD There is an FDA-approved companion diagnostic in lung cancer. But still, a negative liquid biopsy needs to reflex to tumor tissue analysis because not all tumors shed enough DNA. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @stales: @subatomicdoc great question that I've always wondered about. #CancerSm |
| Henning Willers, MD @HenningWillers RT @pfanderson: @HenningWillers @TimAllenMDJD Exactly! Are pathologists accessible to the public? How do you find out who is "your" pathologist? #CancerSM |
| Dee Sparacio @womenofteal #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @subatomicdoc @TimAllenMDJD And #melanoma. https://t.co/nQG9QlN2ff #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage @TimAllenMDJD #cancersm Excellent suggestion! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @drjainsp When someone asks me about a new diagnosis, one of the first things I like to do is search for "questions to ask your doctor" "new diagnosis" [X = topic/diagnosis/disease/procedure/surgery] So often I find very helpful tips! #CancerSM #Medlibs |
| Christina Lizaso @btrfly12 #WTFix #suprisebills |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily i have definitely trouble keeping up!! #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Closing thoughts as we complete our #cancersm twitterchat this evening? |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Get your pathology report and usually there's a phone number. If not, your hospital or clinic should be able to provide it. #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @SpiveySandra Most liquid biopsy tests are not yet covered by insurance. However, most test manufacturers can provide some financial assistance. #cancersm |
| Christina Lizaso @btrfly12 RT @pfanderson: @drjainsp When someone asks me about a new diagnosis, one of the first things I like to do is search for "questions to ask your doctor" "new diagnosis" [X = topic/diagnosis/disease/procedure/surgery] So often I find very helpful tips! #CancerSM #Medlibs |
 | SM RAFIQUL ISLAM @selimshdu RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Liz Salmi @TheLizArmy Anyone with cancer ever get to talk to their pathologist... ever? How did you find them? #btsm #cancersm https://t.co/uFr2z4mgD2 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @SpiveySandra Most liquid biopsy tests are not yet covered by insurance. However, most test manufacturers can provide some financial assistance. #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: @SpiveySandra Most liquid biopsy tests are not yet covered by insurance. However, most test manufacturers can provide some financial assistance. #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Closing thoughts as we complete our #cancersm twitterchat this evening? |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @SpiveySandra Most liquid biopsy tests are not yet covered by insurance. However, most test manufacturers can provide some financial assistance. #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: Get your pathology report and usually there's a phone number. If not, your hospital or clinic should be able to provide it. #cancersm |
| SM RAFIQUL ISLAM @selimshdu RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| SM RAFIQUL ISLAM @selimshdu RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| Liz Salmi @TheLizArmy RT @pfanderson: @HenningWillers @TimAllenMDJD Exactly! Are pathologists accessible to the public? How do you find out who is "your" pathologist? #CancerSM |
| SM RAFIQUL ISLAM @selimshdu RT @drjainsp: T4 For lung cancers, the minimum testing that must be performed is to look at the EGFR gene for mutations and ALK1 and ROS genes for rearrangements. Many pathologists examine other more recently recognized mutations. #cancersm |
| Dee Sparacio @womenofteal Got to run ...#cancersm . Thanks @JFreemanDaily for bringing us all together and @TimAllenMDJD for moderating and everyone who posted. Great Chat! #gyncsm |
 | rieney JFB? @joohyoiun RT theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
 | mary @zebrafinch RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| Henning Willers, MD @HenningWillers @TimAllenMDJD i am gonna have my next #lungcancer patient try that out😇 #cancersm |
| SM RAFIQUL ISLAM @selimshdu RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @TheLizArmy @btrfly12 @BraveBosom I don't Storify =, but I can get @symplur transcript #Cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD This, #Pathologists! #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| National Cancer Institute @theNCI Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
 | SilviaBBCCB @SilviaBBCCB RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @TheLizArmy: Anyone with cancer ever get to talk to their pathologist... ever? How did you find them? #btsm #cancersm https://t.co/uFr2z4mgD2 |
| Pub Health Monitor @monitor_PH RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| Henning Willers, MD @HenningWillers @TimAllenMDJD learned a lot, fantastic chat #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @TimAllenMDJD i am gonna have my next #lungcancer patient try that out😇 #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @womenofteal: Got to run ...#cancersm . Thanks @JFreemanDaily for bringing us all together and @TimAllenMDJD for moderating and everyone who posted. Great Chat! #gyncsm |
| Janet Freeman-Daily @JFreemanDaily Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
 | Sunbeams Are Woke 🇺🇦 🌻 @JackDeTate RT @theNCI: T4 A #liquidbiopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood. #cancersm https://t.co/Qp4ziTm1ad |
| #LCSM Chat @lcsmchat RT @TheLizArmy: Anyone with cancer ever get to talk to their pathologist... ever? How did you find them? #btsm #cancersm https://t.co/uFr2z4mgD2 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| #LCSM Chat @lcsmchat RT @womenofteal: Got to run ...#cancersm . Thanks @JFreemanDaily for bringing us all together and @TimAllenMDJD for moderating and everyone who posted. Great Chat! #gyncsm |
 | James LeRoux @ok_thej14leroux RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage @TimAllenMDJD #cancersm your oncology nurse can help pts access their pathologist |
| Henning Willers, MD @HenningWillers RT @TimAllenMDJD: This, #Pathologists! #cancersm |
| Dennis Keim @denniskeim @HenningWillers @TimAllenMDJD Exactly. I never thought to contact my pathologist. I presumed my onc and GP were adequate and interpretive points of contact there. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @TimAllenMDJD learned a lot, fantastic chat #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It has been my great privilege to participate and my great honor to host tonight's #cancersm twitterchat. My very best to y'all. |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: This, #Pathologists! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| #LCSM Chat @lcsmchat RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| James LeRoux @ok_thej14leroux RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| National Cancer Institute @theNCI RT @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @denniskeim: @HenningWillers @TimAllenMDJD Exactly. I never thought to contact my pathologist. I presumed my onc and GP were adequate and interpretive points of contact there. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @DarcyBurbage: @TimAllenMDJD #cancersm your oncology nurse can help pts access their pathologist |
| #LCSM Chat @lcsmchat RT @DarcyBurbage: @TimAllenMDJD #cancersm your oncology nurse can help pts access their pathologist |
| #LCSM Chat @lcsmchat RT @denniskeim: @HenningWillers @TimAllenMDJD Exactly. I never thought to contact my pathologist. I presumed my onc and GP were adequate and interpretive points of contact there. #cancersm |
 | Antonio Matute (pathology lab. at ABIOSS) @jamatute78 RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: It has been my great privilege to participate and my great honor to host tonight's #cancersm twitterchat. My very best to y'all. |
| Dennis Keim @denniskeim RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
 | Rubens⚡️ @IsRubens RT @theNCI: T3 In many types of cancer, seeing whether the tumor makes the PD-L1 protein can determine whether treatment with a type of #immunotherapy drug called an immune checkpoint inhibitor is appropriate. #cancersm https://t.co/n66X2nteXz |
| Christina Lizaso @btrfly12 There's been a lot of discussion from radiologists lately about directly talking to patients. Now the pathologists are in on it too. Love it. #cancersm |
| Adam L. Booth, MD @ALBoothMD RT @AshleySumrallMD: @TimAllenMDJD T3: @TimAllenMDJD T3: I love this paper outlining tumor types affected by #NTRK fusion. I think we will see even more as we keep testing & building data. #btsm #hncsm #thycsm #cancersm https://t.co/KV6Ct0nXaS |
| Bob Steele @steele_bob RT @TimAllenMDJD: It has been my great privilege to participate and my great honor to host tonight's #cancersm twitterchat. My very best to y'all. |
| Janet Freeman-Daily @JFreemanDaily RT @pfanderson: @JFreemanDaily @peggyddennis I use the analogies of cherry picking (looking at just the most likely & essential ones to save time/cost) and apple harvesting (shaking the tree until everything falls off) #CancerSM |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @israhkhan: #CANCERSM Personalized oncology is based on biomarkers (driver mutations), stage & histology. In lung Ca major biomarkers are : EGFR (10-15% NSCLCs), ALK (2-7%), ROS-1 (1-2%), K-ras (15-30%) are generally mutually exclusive. Cytology material are good substrates for this testing |
| Dennis Keim @denniskeim RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher I love learning from other cancer communities. Together we are stronger. Thanks for organizing this chat @JFreemanDaily #cancersm #MMSM |
 | 🌟 Sherry Reynolds ✨ Person-Centered Health @Cascadia What % of public or private health insurance covers biomarkers - how can people find a list? @TimAllenMDJD @NCI #CANCERSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @btrfly12: There's been a lot of discussion from radiologists lately about directly talking to patients. Now the pathologists are in on it too. Love it. #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock RT @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| Sarika Jain @drjainsp Excellent discussion, very informative. thank you @TimAllenMDJD #cancersm |
| Jamie Holloway, PhD @jamienholloway Can't let a biomarker discussion go by without mentioning the importance of evidence. It's important that any time a drug is suggested based on a biomarker there is data backing that up. #showmethedata #cancersm |
| Christina Lizaso @btrfly12 Fantastic job! Thanks for all you do and thanks #lcsm for rallying us all together. #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @theNCI Thank you for joining! Thank you @TimAllenMDJD for moderating and to everyone from the wonderful Twittersphere for contributing! #cancersm |
| Amanda Haddock 🧬 @AmandaHaddock RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| Christina Lizaso @btrfly12 RT @DarcyBurbage: @TimAllenMDJD #cancersm your oncology nurse can help pts access their pathologist |
| Liz Salmi @TheLizArmy @UppityCancerP @TimAllenMDJD In this age of "meaningful use," where we've had access to: -lab results for a decade -radiology reports for 5 years -clinical notes now for about 12% of the US patients will have easier access to pathology reports into the future. Are pathologists ready to chat? #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @MyelomaTeacher @TheLizArmy @btrfly12 @BraveBosom @symplur I will make a Wakelet and tweet it out later tonight. #CancerSM |
| Amanda Haddock 🧬 @AmandaHaddock RT @TimAllenMDJD: This, #Pathologists! #cancersm |
| Sandra Spivey @SpiveySandra @JFreemanDaily Yes $ assistance from test mfgs. For certain income levels and below. If you've saved too much for retirement, you're out of luck. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD @JFreemanDaily #LikeABoss #cancersm |
| Dennis Keim @denniskeim RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| Christina Lizaso @btrfly12 RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| Christina Lizaso @btrfly12 RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage Thanks .@TimAllenMDJD #CANCERSM & all who participated! Very informative! |
| Sarika Jain @drjainsp We are just a phone call away #pathologists |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Absolutely! #cancersm |
 | cacaskata @cacaskata RT @TimAllenMDJD: T5: T5: It's always a good idea to ask your doctor about molecular testing; but given the confusion in this rapidly changing area, it may be difficult to know what to ask your doctor. Feel free to call your pathologist and discuss! #cancersm |
 | Regina Garbie @GarbieRegina RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @jamienholloway: Can't let a biomarker discussion go by without mentioning the importance of evidence. It's important that any time a drug is suggested based on a biomarker there is data backing that up. #showmethedata #cancersm |
| Janet Freeman-Daily @JFreemanDaily Thanks for sharing the link to @NCCN guidelines, @btrfly12! #cancersm #lcsm #btsm #bcsm #mmsm #ayacsm #gyncsm |
| Liz Salmi @TheLizArmy @HenningWillers @TimAllenMDJD I just met you Dr. Willers, but I like your style. #cancersm https://t.co/VDAB8zvSrE |
| Antonio Matute (pathology lab. at ABIOSS) @jamatute78 I Belive the most important use of LB could be relepse prevention, or early mets detection |
| Israh Akhtar Khan @israhkhan @TimAllenMDJD #CANCERSM that was a great discussion, !!! |
| Christina Lizaso @btrfly12 RT @TheLizArmy: @UppityCancerP @TimAllenMDJD In this age of "meaningful use," where we've had access to: -lab results for a decade -radiology reports for 5 years -clinical notes now for about 12% of the US patients will have easier access to pathology reports into the future. Are pathologists ready to chat? #cancersm |
 | Amanda Jayne Griffin 🎗 @erinforever14 RT @theNCI: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: T4 And here’s an overview from 2017 of the evolving science around liquid biopsies and the important research questions: https://t.co/zqj48vhMbG #liquidbiopsy #cancersm |
| Christina Lizaso @btrfly12 RT @jamienholloway: Can't let a biomarker discussion go by without mentioning the importance of evidence. It's important that any time a drug is suggested based on a biomarker there is data backing that up. #showmethedata #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Thank - you - for your great perspective! #cancersm |
 | someprivate @someprivate RT @theNCI: T4 A #liquidbiopsy may be used to help find cancer at an early stage. #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @pfanderson @TheLizArmy @btrfly12 @BraveBosom @symplur Wakelet?! That's new to me.. :) #Cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc Good to see everyone - have a great night! #cancersm |
| Sandra Spivey @SpiveySandra @theNCI Will the chat be summarized and posted? #cancersm |
| Bob Steele @steele_bob Most excellent Cancer Social Media Twitter chat session tonight. Recognition of expanded commonality of causes bodes well for all. #cancersm |
| Liz Salmi @TheLizArmy @TimAllenMDJD Thank you, Dr. Allen, for moderating this really great chat! Thanks to @lcsmchat for bringing the whole community together. On behalf of @BTSMchat and #BTSM, thank you for including your cousins in the brain tumor community. 🙏 #cancersm |
| Jamie Holloway, PhD @jamienholloway Awesome biomarker chat tonight at #cancersm! Thanks for hosting @TimAllenMDJD and @lcsmchat! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that @jamienholloway #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @btrfly12: T5: T5: Second opinions are almost always a good idea - especially in cancer. Seek doc's with high case volume of your specific type of cancer. You are you own best advocate and the science is changing fast. #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Thanks for sharing the link to @NCCN guidelines, @btrfly12! #cancersm #lcsm #btsm #bcsm #mmsm #ayacsm #gyncsm |
| Liz Salmi @TheLizArmy RT @jamienholloway: Can't let a biomarker discussion go by without mentioning the importance of evidence. It's important that any time a drug is suggested based on a biomarker there is data backing that up. #showmethedata #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @pfanderson: @MyelomaTeacher @TheLizArmy @btrfly12 @BraveBosom @symplur I will make a Wakelet and tweet it out later tonight. #CancerSM |
| cacaskata @cacaskata RT @AshleySumrallMD: Hey @TimAllenMDJD, while we mention biomarkers, I have to mention @ASCO #TAPUR as an awesome example of a clin trial based on biomarkers. Also a great example of multiple clinicians working together. #cancersm https://t.co/UC2C1Da7RO |
| someprivate @someprivate RT @theNCI: T4 A liquid biopsy may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Taking multiple samples of blood over time may also reveal the molecular changes taking place in a tumor. #cancersm #liquidbiopsy https://t.co/gaBX0Qvr3H |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @Cascadia: What % of public or private health insurance covers biomarkers - how can people find a list? @TimAllenMDJD @NCI #CANCERSM |
 | ナオミ @nao73714 RT @theNCI: Thank you, everyone, for a fascinating and informative chat! If you have questions about cancer or biomarkers, please reach out to our Cancer Information Service: https://t.co/I0exZMw6s3 If you asked a question tonight, we will try to get you an answer! #cancersm |
| Christina Lizaso @btrfly12 @MyelomaTeacher @pfanderson @TheLizArmy @BraveBosom @symplur I think Storify went away and now is Wakelet. Let's you pull the tweets together and arrange, weed out RTs etc. = Fancy, editable transcript. I did register #cancersm with @healthhashtags so should be available soon. |
| National Cancer Institute @theNCI @SpiveySandra Retweeting @JFreemanDaily: Thanks to @TimAllenMDJD for the blog and great job a moderator. And thanks for so much great info from @NCI and so many others! Terrific chat. We'll summarize it on Wakelet in the next several days. #cancersm |
| Henning Willers, MD @HenningWillers RT @TheLizArmy: @UppityCancerP @TimAllenMDJD In this age of "meaningful use," where we've had access to: -lab results for a decade -radiology reports for 5 years -clinical notes now for about 12% of the US patients will have easier access to pathology reports into the future. Are pathologists ready to chat? #cancersm |
| Dennis Keim @denniskeim RT @theNCI: T1 A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. https://t.co/uCNkV7yF4T #cancersm https://t.co/qxvO2FOQI0 |
| Dennis Keim @denniskeim RT @drjainsp: T4 There are guidelines for what biomarker testing must be performed on different cancer types. https://t.co/0NmT5EaL4E #cancersm |
 | Geska Lima @Geskalima RT @theNCI: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: T4 From NCI’s Cancer Currents blog last year: Liquid biopsy may predict the risk of breast cancer returning years later: https://t.co/zuL4GnA0CV #liquidbiopsy #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson @btrfly12 @MyelomaTeacher @TheLizArmy @BraveBosom @symplur @healthhashtags Storify died after it was bought. Wakelet was a competing product that really beefed up their game, and has been enormously responsive to co-development with users. In many ways, superior to Storify #CancerSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Thank you, @theNCI, for your valuable contributions to tonight's #cancersm twitterchat! |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @TheLizArmy: @UppityCancerP @TimAllenMDJD In this age of "meaningful use," where we've had access to: -lab results for a decade -radiology reports for 5 years -clinical notes now for about 12% of the US patients will have easier access to pathology reports into the future. Are pathologists ready to chat? #cancersm |
| Sandra Spivey @SpiveySandra @UppityCancerP @JFreemanDaily Retired early because I didn't have the energy to work like I did my first 10 years after dx'd with #metastaticbc When I was dx'd with MBC in 1998, I thought about how my husband would spend all of our hard-earned savings after I die and then cry. Good luck w/scans #cancersm |
| Christina Lizaso @btrfly12 RT @TimAllenMDJD: Thank you, @theNCI, for your valuable contributions to tonight's #cancersm twitterchat! |
| Janet Freeman-Daily @JFreemanDaily Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: https://t.co/Y19PJa0dvE #cancersm #lcsm #bcsm #btsm #gyncsm #mmsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #cancersm FTW |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher @btrfly12 @pfanderson @TheLizArmy @BraveBosom @symplur @healthhashtags Thanks I just signed on to @symplur and #cancersm wasn't available yet , I hope I remember to check back. Damn chemo-brain if I don't do things right away I forget to do them. |
| National Cancer Institute @theNCI RT @JFreemanDaily: Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: https://t.co/Y19PJa0dvE #cancersm #lcsm #bcsm #btsm #gyncsm #mmsm |
| Janet Freeman-Daily @JFreemanDaily @btrfly12 @MyelomaTeacher @pfanderson @TheLizArmy @BraveBosom @symplur @healthhashtags Thanks for registering the hashtag! Transcript for tonight's #cancersm chat is here: https://t.co/Y19PJa0dvE |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Let's do it again sometime! #cancersm |
 | Lisa (Loehr)Spaulding @leezawilllshe RT @jamienholloway: T5: T5: Easiest tweetchat answer ever. #cancersm https://t.co/9jxX9jnvIW |
#cancersm content from Twitter.